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CRYSTALLOGRAPHIC ANALYSIS AND KINETIC STUDIES OF
HIV-1 PROTEASE AND DRUG-RESISTANT MUTANTS
by
YUNFENG TIE
Under the Direction of Irene T. Weber

ABSTRACT
HIV-1 protease is the most effective target for drugs to treat AIDS, however, the
long-term therapeutic efficiency is restricted by the rapid development of drug resistant
variants. To better understand the molecular basis of drug resistance, crystallographic and
kinetic studies were applied to wild-type HIV-1 protease (PR) and drug-resistant mutants,
PRV82A, and PRI84V, in complex with substrate analogs, the current drug saquinavir and
the new inhibitor UIC-94017 (TMC-114). UIC-94017 was also studied with mutants
PRD30N and PRI50V. The drug-resistant mutations V82A, I84V, D30N and I50V
participate in substrate binding. Eighteen crystal structures were refined at resolutions of
0.97-1.60Å. The high accuracy of the atomic resolution crystal structures helps
understand the reaction mechanism of HIV-1 PR.
Different binding modes are observed for different types of inhibitors. The
substrate analogs have more extended interactions with PR subsites up to S5-S5’, while
the clinical inhibitors maximize the contacts within S2-S2’. Hydrophobic interactions are
the major force for saquinavir binding since it was designed with enhanced hydrophobic
groups based on substrate side-chains. In contrast, the new clinical inhibitor UIC-94017

was designed to mimic the hydrogen bonds between substrates and PR. UIC-94017 forms
polar interactions with the PR main-chain atoms of Asp29/30, which have been proposed
to be critical for its potency against resistant HIV.
The mutants showed different structural and kinetic effects, depending on the
inhibitor and location of the mutations. The observed structural changes were consistent
with the relative inhibition data. Both PRI84V and PRI50V lost favorable hydrophobic
interactions with inhibitor compared with PR. Similarly, in PRD30N the UIC-94017 had a
water-mediated interaction with the side-chain of Asn30 rather than the direct interaction
observed in PR. However, PRV82A compensated for the mutation by shifts of the
backbone of Ala82. Furthermore, the complexes of PRV82A showed smaller shifts relative
to PR, but more movement of the peptide analog, compared to complexes with clinical
inhibitors. The structures suggest that substrate analogs have more flexibility than the
drugs to accommodate the structural changes caused by mutation, which may explain
how HIV can develop drug resistance while retaining the ability of PR to hydrolyze
natural substrates.

INDEX WORDS: HIV-1 protease, drug resistance, V82A, I84V, D30N, I50V, substrate
analog, UIC-94017, TMC-114, saquinavir, crystal structure, kinetics.
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Crystallographic analysis and kinetic studies of
HIV-1 protease and drug-resistant mutants
1. Introduction
1.1. General introduction
Current general situation of AIDS
Two decades ago the first case of the acquired immunodeficiency syndrome
(AIDS) was recognized in the United States. By 2005, more than 40 million people are
known to be infected with AIDS and more than 25 million people have died of AIDS
(AVERT). AIDS is now the fourth-biggest killer globally. Currently, no cure or effective
vaccine has yet been developed, but modern clinical treatment, Highly Active Antiretroviral Therapy or HAART, is available to extend and improve the lives of patients
afflicted with AIDS. HAART reduces viral load and prevents many opportunistic
infections associated with AIDS. However, AIDS is still a fatal disease and even
HAART is not widely available outside high-income developed countries because of its
high cost. Thus, it is critically important to improve current clinical accessible treatments,
and more efforts should be put into the research to continue extending such advances.
More effective and low-cost drugs need to be designed, tested and supplied to many
developing countries.
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The HIV-1 life cycle
AIDS is caused by human immunodeficiency virus type 1 (HIV-1), a member of
the family of retroviruses that possess complex genomes and exhibit cone-shaped capsid
core particles (Barre-Sinoussi et al. 1983; Gallo et al. 1984; Levy et al. 1984). Other
examples of retroviruses include the simian immunodeficiency virus (SIV), bovine
leukemia virus (BLV), human T-cell leukemia virus type-1 (HTLV-1), and equine
infectious anemia virus (EIAV). As a characteristic of all retroviruses, HIV's genome is
encoded by RNA. The viral reverse transcriptase (RT) will reverse-transcribe RNA to
viral DNA when virus enters a new host cell. The general features of the mature HIV
virion and ribbon representations of the structurally characterized viral proteins are
shown in Figure 1.1 (Turner et al. 1999). The surface of virus is a lipid bilayer embedded
by envelope proteins (SU) which is derived from the membrane of its host. The middle
part is a matrix shell composed by matrix protein (MA) and a capsid core particle
comprising of the capsid protein (CA). The inner of the capsid particle contains two
copies of the unspliced viral genome and three most essential viral enzymes: protease
(PR), reverse transcriptase (RT) and integrase (IN).
Figure 1.2 (Turner et al. 1999) presents the general scheme of the HIV replication
cycle. It contains six steps. The replication cycle starts by the binding of the virus
envelope protein to CD4 on the cell surface, a protein that normally functions in immune
recognition. The viral protein then fuses into the cell membrane (Doranz et al. 1996; Feng
et al. 1996; Clapham et al. 1997; Moore 1997). After uncoating of the virus, an
intracellular reverse transcriptase (RT) catalyzes the reverse transcription of the viral
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Figure 1.1 Representation of the mature HIV-1 virion surrounded by the known
structures of the viral proteins and protein fragments. (Turner et al. 1999)

4

Figure 1.2 General features of the HIV-1 life cycle. (Turner et al. 1999)
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RNA in the cytosol. The mechanism of this RT-dependent DNA synthesis has been well
studied in vitro and in vivo (Goff 1990; Whitcomb et al. 1992; Skalka et al. 1993; Katz et
al. 1994; Telesnitsky et al. 1997). Once synthesized, the viral cDNA is translocated to the
nucleus with matrix protein, IN and other viral proteins as a preintegration complex
(Miller et al. 1997). The nuclear localization of the preintegration complex is directed by
the accessory protein Vpr (Freed et al. 1995; Fouchier et al. 1997; Nie et al. 1998). The
viral cDNA is then integrated into the host genome by the catalytic action of IN. The
integration process also requires a host chromosome protein. Multiple unspliced and
spliced mRNA are synthesized and transported out of the nucleus for translation. The
translation is a very complicated process initialized by the synthesis of regulatory
proteins Tat, Rev and Nef, and then the polypeptides: Gag and Gag-pol and protease are
formed. Viral RNA and proteins assemble at the host cell surface and buds from the cell
surface to form an immature particle. Finally, as protease cleaves polyproteins into
structural proteins, such as the MA, CA and NC and functional enzymes (including
itself), the structural proteins rearrange and form the mature infectious virus particle. The
whole life cycle is usually divided into two phases: the early phase ends with the
integration of the viral genetic information into the chromosome of the host cell, while
the late phase includes viral protein expression and virus maturation (Turner et al. 1999;
Freed 2001).
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The purpose of studying HIV-1 protease
Obviously, through the HIV replication cycle, the retroviral enzymes: reverse
transcriptase (RT), integrase (IN), and protease (PR) are three important targets for drug
discovery and PR has proved to be the most effective one. PR is required for proteolytic
cleavage of viral polyprotein precursors Gag and Gag-Pol into individual structural and
functional proteins during viral maturation (Darke et al. 1988; Oroszlan et al. 1990).
Two steps are critical in this process: one is the formation of an active PR dimer from
two Gag-Pol precursors, which is crucial for the release of mature PR; the other is the
cleavage at the N terminus of the PR which is necessary for the liberation of catalytic
activity (Louis et al. 1994) and optimal ordered processing of the Gag and viral
infectivity (Tessmer et al. 1998).
In HIV-1, the Gag polypeptide is composed of structural proteins in the
arrangement of MA-CA-p2-NC-p1-p6 (Genbank: HIVHXB2CG) (Henderson et al. 1992;
Wondrak et al. 1993), while Gag-Pol of MA-CA-p2-NC-TFR-PR-RT-IN (Louis et al.
2000), as shown in Figure 1.3. A protease cleavage site separates each of the subdomains
on the polyprotein and the numbers (Figure 1.3) represent the order of cleavage. The
ordered process of polypeptides is controlled by different intrinsic proteolysis rates at the
different cleavage sites (Wiegers et al. 1998). The catalytic activity of the mature PR and
sequential processing of the polyproteins have been shown to be critical for the liberation
of infective progeny virus (Oroszlan et al. 1990; Debouck 1992; Rose et al. 1998).

7

Figure 1.3 Composition of the Gag and Gag-Pol polyproteins and HIV-1 PR
cleavage sites. The number represents the order of cleavage of the polyproteins with 1
for the first and 3 for the last.
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Structural properties of HIV-1 protease
HIV-1 PR has 99 amino acid residues and is enzymatically active as a homodimer under acidic conditions. It is a member of the aspartic protease family. Crystal
structures have been determined for HIV PR in the absence and presence of inhibitor, as
reviewed in (Wlodawer et al. 1993) (Figure 1.4B). The two chemically identical subunits
are arranged in a nearly symmetric manner. Each subunit folds into a compact structure
of β-strands with a short α-helix near the C terminus. As shown in Figure 1.4A, the Nterminal residues 1–4 forms β-strand a, which is the outer part of the interface β-sheet.
Residues 9–15 forms β-strand b and through a turn, continue into β-strand c, which ends
at the active-site triplet (Asp25-Thr26-Gly27). Following the active-site loop is β-strand
d consisting of residues 30–35. A broad loop (residues 36–42) links to β-strand a’ formed
by residues 43–49. Residues 52–66 forms a long β-chain b’ and the β-chain c’ comprises
residues 69–78. After a loop by residues 79–82, short strand d’ (residues 83–85) leads
directly to the only α-helix h (residues 86–94). Helix h is followed by a straight Cterminal strand q (residues 95–99), which forms the inner part of the dimer interface.
Four of the β-strands in the molecular core are organized into a ψ-shaped sheet
characteristic of all aspartic proteases.
Residues 44-57 in each subunit create a flexible “flap” composed of a pair of antiparallel β-strands (a’ and part of b’). Inhibitors or substrates bind between two subunits
in the dimer by hydrogen bonds and van der Waals interactions with the active site,
which consists of two characteristic triplets and two flexible flaps. The flaps fold down
over the substrate or inhibitor and act during catalysis both to bind substrate and exclude

9

A.

B.
Figure 1.4 Ribbon drawing of HIV-1 PR structure.
A. Representation of secondary structure for PR with inhibitor (or substrate).
B. PR structures with / without inhibitor (or substrate). Red one presents PR with
binding of inhibitor (or substrate) and blue for PR without inhibitor (or substrate).
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water molecule from the active site (Figure 1.4B) (Wlodawer et al. 1993; Louis et al.
2000). There is a conserved buried water molecule that bridges the inhibitor and Ile50/50’
NH groups of the flaps. This water has proved to be essential for the PR hydrolysis and
could be displaced by a carbonyl group in an appropriately designed inhibitor (Lam et al.
1994). NMR studies confirmed the displacement of the water molecule (Wang et al.
1996) and also verified the presence of other structurally important water molecules
(Grzesiek et al. 1994). NMR studies also confirmed that the PR flaps are indeed flexible,
and suggest that this flexibility may be important for enzyme activity (Nicholson et al.
1995; Yamazaki et al. 1996). Mutation of flap residues can cause dramatic reduction in
enzyme activity (Tozser et al. 1997). Besides the catalytic triad, Gly86-Arg87-Asn88 in
HIV-1 PR is another highly conserved region in retroviral proteases which may
contribute to dimer formation (Louis et al. 1989). It has been reported that either mutating
catalytic residues at the active site (Kohl et al. 1991) or disrupting the dimerization of
active HIV-1 protease monomers (Zhang et al. 1999) will eliminate the catalytic activity
of the PR and thus block the infectivity of the virus.
Although the native protein is a symmetric dimer, inhibitors bind in an
asymmetric manner, as must the natural protein substrates. The substrate binding site
consists of subsites S3 to S4’ and is mainly formed by residues 8, 23-30, 32, 45-50, 53,
56, 76, 80-82 and 84. PR residues 1-3, 5-9, 23-27, 29, 47-52, 54, 67, 81, 87 and 90-99
contribute to the dimer interface contacts.
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Catalytic mechanism of HIV-1 PR
The catalytic mechanism of HIV-1 PR is still controversial. HIV PR is a member
of the aspartic protease family. The reaction involves two catalytic Asps and one or two
flap regions are important for substrate binding and catalysis. The retroviral PRs, like
HIV PR, have differences in their tertiary and quaternary structures compared to the
cellular or pepsin-like proteases. HIV PR is catalytically active as a dimer with one
catalytic aspartic acid and one flap from each subunit, while pepsin-like proteases act as
monomers with one catalytic Asp from each of two domains and generally a single flap
region. Kinetic studies and molecular dynamic simulations have been used to explore
the detailed mechanism but it is hard to demonstrate the feasibility of a particular
mechanism. Overall, the reaction is a general-acid/general-base catalysis and involves
both physical changes (such as the folding down of the flaps over substrate) and chemical
steps (formation and dissociation of a tetrahedral intermediate). Unlike the serine and
cysteine proteases, no covalent acyl-enzyme intermediate is formed during this process.
The efficiency of the cleavage depends on the amino acid sequence of the substrate
(Polgar et al. 1994).
The general catalytic mechanism of HIV-1 PR was proposed by Hyland (Hyland
et al. 1991) by kinetic measurements, and is very similar to the “push-pull” mechanism of
cellular aspartic proteases (Polgar 1987). The catalytic Asp25 residues from both
subunits interact closely at the subunit interface and dispose on opposite faces of the
peptide bond to be cleaved. One Asp (Asp-COO-) which is un-protonated acts as the
general base to activate the attacking H-OH, and the second Asp (Asp-COOH) which is
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protonated acts as the general acid to protonate the departing amine product. After the
formation of a tetrahedral intermediate, the two aspartic acids act in a complementary
fashion for breakdown of the tetrahedral adduct (Figure 1.5A). Moreover, Hyland
suggested a possible change in rate-limiting step from a chemical one coupled with
proton transfer at high pH to a physical one in which a product release step or an enzyme
isomerization step becomes partly rate-limiting at low pH. Kinetic experiments of
different substrates by Polar indicated that the rate-limiting step can be either a chemical
step or a physical step depending on the charge of the residue in P2’. A charged residue at
P2’ can alter the nature of the enzyme-substrate complex and result in different
mechanisms for the different substrates (Polgar et al. 1994). Later studies by Szeltner
and Polgar showed that, independent of the salt concentration, the rate-limiting step of
the catalysis is a chemical process rather than a physical one (Polgar et al. 1994). Besides
the argument of the rate-limiting step, other debate regarding the catalytic process is
which Asp is protonated and where the H2O molecule is from. One possibility is the
conserved water molecule between the PR flaps and the inhibitor observed in most
crystal structures. However, this water molecule is located at the opposite side of the
cleaved peptide bond and far away from the catalytic Asps; so to be able to attack the
catalytic Asp, energy would be needed to transfer it to a proper position between the
catalytic Asps and substrate. Studies by Baca have shown that the hydrogen bonds
between this water molecule and the PR flaps do not contribute to the binding of
substrate, but are essential for normal turnover of substrate under steady-state conditions
by chemically modified PR (Baca et al. 1993). Molecular dynamics simulation studies by
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Figure 1.5 Reaction mechanism of HIV-1 PR.
A. One reaction mechanism proposed by Hyland (Hyland et al. 1991).
B. Another mechanism for the formation of reaction intermediate proposed by
Harrison (Harrison et al. 1994).
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Chatfield further suggested that this H2O does not participate directly in the reaction but
stabilizes productive conformations of reactants and intermediates, and in addition, there
would be a lytic H2O near the active site with very little mobility to act as nucleophilic
water (Chatfield et al. 1995). The latter assumption can hardly agree with the crystal
structures of HIV-1 PR with transition-state analog inhibitors because there is no space
for such a water molecule near the catalytic aspartic residues. Some other studies of
pepsin-like proteases have suggested that there was a water/solvent molecule between the
two catalytic Asps and at a hydrogen bonding distance from all four oxygen atoms in the
crystal structures without bound inhibitor and this water/solvent might act as the
nucleophile (Pearl et al. 1984; Suguna et al. 1987). However, the mechanism of HIV-1
PR could be different from that of pepsin-like aspartic proteases. Crystal structures
suggested the presence of a uranyl ion at similar site of Rous sarcoma virus PR (Miller et
al. 1989) and HIV-1 PR structure in the absence of inhibitor (Wlodawer et al. 1989).
Thus, Harrison had analyzed another possibility by molecular dynamics simulations
(Harrison et al. 1994). As shown in Figure 1.5B, after substrate binds (A), the proton
moves from the protonated Asp to the carbonyl oxygen on the substrate and the positive
charge is stabilized by the Asps (B). The protonated carbonyl carbon is then attacked by a
nucleophile, such as water, to form the transition-state intermediate (B, C). The gem-diol
groups are unstable and will rapidly break down to release two product peptides. The
proton is restored. In this case, the water molecule is attacking from the opposite side of
the scissile bond so the flap water molecule mentioned above becomes an ideal
nucleophile in processing the reaction. Moreover, once the reaction completes, this H2O
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will no longer stabilize the protease/substrate binding and facilitate the dissociation of the
peptide products. A recent quantum-classical molecular dynamics simulations by Trylska
has proposed another direct nucleophilic mechanism in which the un-protonated Asp25
acts as a nucleophile and attacks the peptide carbon of the substrate, and tried to test the
possibility of this direct mechanism and general-acid/general-base mechanism, but no
conclusions have been made at this stage (Trylska et al. 2004).

Substrate preference of HIV-1 PR
The naturally occurring cleavage site sequences on Gag and Gag-Pol polyprotein
are listed in Table 1.1. The sequences are quite diverse, but still show certain preferences.
At P1 and P1’, on either side of the cleavage bond, hydrophobic residues dominate, but
Val and Ile are absent. Pro appears frequently at P1’ but never at P1, instead, Phe is the
most frequent amino acid at P1. Small hydrophobic or polar residues occupy P2 and P2’
and more diversity is found at the outer positions. The subsite preference has also been
studied by enzyme kinetics using oligopeptide substrates. The PR can not hydrolyze
peptides with β–branched amino acids, such as Val, substituted in the P1 position, as well
as Pro, Ser or Gly (Phylip et al. 1990; Tozser et al. 1992). Charged amino acids, such as
Arg and Glu, at P1 or P1’ positions are also not preferred in substrates (Konvalinka et al.
1990; Cameron et al. 1993). In agreement with the natural cleavage site sequences, HIV
PR prefers small hydrophobic residues at P2 and can accommodate various residues at P3

Table 1.1 Protease cleavage sites in HIV-1 Gag and Gag-Pol polyproteins (Louis et al. 2000).
Location of the
cleavage site

P4

P3

P2

P1

P1’

P2’

P3’

MA-CA

Ser

Gln

Asn

Tyr

Pro

Ile

Val

CA-p2

Ala

Arg

Val

Leu

Ala

Glu

Ala

p2-NC

Ala

Thr

Ile

Met

Met

Gln

Arg

NC-p1

Arg

Gln

Ala

Asn

Phe

Leu

Gly

p1-p6

Pro

Gln

Asn

Phe

Leu

Gln

Ser

in p6

Lys

Glu

Leu

Tyr

Pro

Leu

Thr

TFP-p6pol

Asp

Leu

Ala

Phe

Leu

Gln

Gly

p6pol-PR

Ser

Phe

Asn

Phe

Pro

Gln

Ile

PR-RT

Thr

Leu

Asn

Phe

Pro

Ile

Ser

p66-p51

Ala

Glu

Thr

Phe

Tyr

Val

Asp

RT-IN

Arg

Lys

Ile

Leu

Phe

Leu

Asp

In Gag

In Pol
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and P3’ while the P2’ preference depends on the amino acid of P1 and P1’ (Konvalinka et
al. 1990; Tozser et al. 1991a; Tozser et al. 1991b; Tozser et al. 1992; Cameron et al.
1993).

Drug-resistance
Since the reverse transcriptase inhibitor, azidothymidine (AZT), previously
known as a potential anticancer agent, was first approved by the U.S. Food and Drug
Administration (FDA) for treating AIDS in 1987, seven FDA-approved RT inhibitors and
eight PR inhibitors (PIs) have become commercially available. The protease inhibitors
are saquinavir, amprenavir (and fosamprenavir), indinavir, nelfinavir, ritonavir,
atazanavir, lopinavir and tipranavir (chemical structures shown in Figure 1.6). The
combination therapy using protease inhibitors as well as inhibitors of reverse
transcriptase has had a great impact in extending the life of AIDS patients (Gulick et al.
1997; Palella et al. 1998). However, the long-term therapeutic efficiency is restricted by
the rapidly development of drug resistant variants (Tamalet et al. 2000).
Similar to other retroviral polymerases, HIV RT does not have a proofreading
function (Roberts et al. 1988; Ji et al. 1992) and thus increases the mutational rates of the
virus. Divergent viral populations are present during infection and the proteases from
these different strains differ in their sequences. Besides, HIV virus has high replication
capability. In a fully infected patient about 109 virus particles are produced every day (Ho
et al. 1995; Wei et al. 1995). It has been estimated that at least 109 new cells are infected
daily in latent HIV-infected patients, and the point mutation occurs at the rate of 105
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Figure 1.6 Chemical structures of currently eight FDA-approved HIV protease
inhibitors (Part 1).
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Figure 1.6 Chemical structures of currently eight FDA-approved HIV protease
inhibitors (Part 2).
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times per day along the entire length of the genome (Coffin 1995). Many of these
mutations do not affect the activity of the enzyme, and the structures of fully active
proteases that differ in sequences have been reported. However, the virus with certain
drug-resistant mutations apparently can be retained in patients’ body and is not
susceptible to current drugs (Chun et al. 1997; Finzi et al. 1997; Wong et al. 1997). High
rates of viral turnover rate may eventually produce high populations of resistant virus
during antiviral therapy due to drug selection of viral strains (Boucher 1996). It has been
reviewed that 62 mutations of 43 different residues in HIV-1 PR were associated with
drug resistance (Hammond et al.; Johnson et al. 2005). The drug-resistant level of some
of these mutants versus seven current PIs is shown in Figure 1.7 and their positions in PR
structure are mapped in Figure 1.8. Furthermore, cross-resistance has been reported in
AIDS patients on combination therapy (Shafer et al. 1998; Hertogs et al. 2000).
The mechanism for the development of resistance to PIs is quite complicated. As
shown in Figure 1.8, the locations of PI-resistant mutations vary from substrate/inhibitor
binding site, dimer interface, and flap region to surface of PR. One explanation is that the
residues near the active site can directly interfere with the binding of the inhibitor to the
enzyme by modifying its specificity and/or affinity. Another cause for those mutations
which do not directly change the shape or property of the binding cavity is that they may
affect the efficiency of catalysis and the stability of the PR (Gulnik et al. 1995;
Mahalingam et al. 1999), or influence enzyme active site via long-range structural
perturbations. Still, drug resistance can be caused by various reasons or combination of
different subtle changes.
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Figure 1.7 Drug resistant level of different mutants against seven FDA approved
PIs. (http://hivdb.stanford.edu/cgi-bin/PIResiNote.cgi)
I) Major mutations. With the exception of L90M, these mutations are in the substrate
cleft site. Each by itself is capable of reducing susceptibility to one or more PIs. With the
exception of V82I, which does not cause drug resistance, mutations at these positions are
nonpolymorphic in that they do not occur in PI-naïve persons. II) Flap mutations. These
mutations are in the protease flap and are second in importance only to the major
mutations. Some may cause resistance by themselves, but these mutations are more often
accessory. They are also nonpolymorphic. III) Other nonpolymorphic PI-resistance
mutations. These mutations indicate past PI exposure. Several cause resistance by
themselves but more often they are accessory. IV) With the exception of L10F, these
mutations are polymorphic. They contribute to resistance only when present in
combination with one or more category I-III mutations.
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Figure 1.8 Sites of drug resistant mutations on PR dimer.
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1.2 Rationale and Specific Aims
Up to today, more than 240 crystal structures of HIV-1 PR and PR-inhibitor
complexes were determined (PDB), most of which were used to guide the development
of protease inhibitors. Indeed, these efforts have illustrated enormous potential and utility
of the rational structure-based drug design strategy. However, the molecular basis for the
drug resistance is still not fully understood. The long-term effectiveness of antiviral
treatment is severely limited by the drug resistance and narrow choices of available
drugs. To address this question and design more effective PIs to combat drug resistance,
crystallographic and kinetic studies were applied to wild-type HIV-1 protease and drugresistant mutants, PRV82A, and PRI84V, in complex with substrate analogs, current drug
saquinavir and latest design UIC-94017 (also called TMC-114). UIC-94017 was also
studied with PRD30N and PRI50V. Crystal structures of some resistant mutants have
provided the molecular basis for the altered enzymatic properties and the resistant
phenotype (Hong et al. 2000; Mahalingam et al. 2001; Mahalingam et al. 2002; PrabuJeyabalan et al. 2003). These studies of detailed structural information and kinetic
properties suggested that individual mutations, double or multiple mutations, had a range
of effects, such as changed binding affinity, catalytic activity and dimer stability, which
depend on the specific combination of mutant with substrate or inhibitor. Therefore, it is
important to obtain high-resolution crystal structures in order to observe the small
structural changes associated with the mutations.
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The purpose of choosing PR and mutants PRV82A, PRI84V, PRD30N and PRI50V
Mutations in the substrate binding site can cause resistance by reducing the PR
binding affinity by 2~5-fold for inhibitors (Erickson et al. 1999). Resistant mutations are
commonly observed at D30, M46, I50, V82 and I84 (Shafer et al. 1998; Shafer 2002).
Mutations of residue 82 show decreased susceptibility to indinavir, ritonavir, and
lopinavir in vitro; PRV82A is the most common mutation at this position. Mutation V82A
is observed predominantly in HIV-1 isolates from patients receiving treatment with
indinavir and ritonavir (Condra et al. 1996; Molla et al. 1996). It also occurs in isolates
from patients receiving prolonged therapy with saquinavir after the development of the
mutation G48V (Winters et al. 1998). Mutation I84V has been reported in patients
receiving indinavir, ritonavir, saquinavir, and amprenavir (Hertogs et al. 2000; Maguire
et al. 2002). It causes phenotypic and clinical resistance to each PR inhibitor (Kempf et
al. 2001; Prado et al. 2002; Colonno et al. 2003). I84V mutation tends to develop in
isolates that already have the mutation L90M and is rarely the first major mutation to
develop in patients receiving a PR inhibitor (Wu et al. 2003). Mutations D30N and I50V
were especially chosen to study with UIC-94017. PRD30N was selected because Asn30
was expected to affect the hydrogen bond interaction between Asp30 side chain and the
aniline group of UIC-94017. PRD30N occurs solely in patients receiving nelfinavir and
confers to reduce nelfinavir susceptibility by 5-20 fold (Jarvis et al. 1998; Markowitz et
al. 1998; Patick et al. 1998). The Asp-to-Asn mutation neutralized negative charge on
aspartic acid without significantly changing the geometry of the side chain. Previous
study in our group suggested that PRD30N had varied activity for the hydrolysis of
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peptides resembling different Gag and Gag-Pol cleavage sites while retaining its stability
compared to the wild type PR (Mahalingam et al. 1999). Crystal structures of PRD30N in
complexes with substrate analogs corresponding to CA-p2 and p2-NC cleavage sites
revealed distinct changes in the position of the Asn30/30’ side chains when they were
compared to each other or to the wild type structures, in agreement with the observed
different specificity (Mahalingam et al. 2001). Mutation I50V was selected for study
since HIV with this mutation shows intermediate-to-high level resistance with
amprenavir (Maguire et al. 2002) and low resistance to ritonavir and lopinavir (Partaledis
et al. 1995; Tisdale et al. 2000; Prado et al. 2002). Since UIC-94017 was designed based
on the chemical structure of amprenavir, the analysis of PRI50V/UIC-94017 complex will
help evaluate the effectiveness of potent compound UIC-94017. The mutation from Ile to
Val reduces the size of the hydrophobic side chain by one methyl group and is expected
to increase the size of the binding cavity and reduce the affinity for inhibitor.

The specific aims of my investigations are as follows:
Aim 1: To determine & analysis crystal structures of PR and mutants PRV82A and
PRI84V with peptide analogs.
HIV PR hydrolyzes several different cleavage sites in the natural polyprotein
substrates. The cleavage sites share little sequence homology (as shown in Table 1.1) so
the specificity of the PR is not fully defined. Furthermore, the mechanisms for how the
mutants maintain sufficient enzymatic activity for viral replication can be better
understood by studying the structures of PR with natural cleavage sites. Two alternative
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strategies have been applied to overcome the difficulty of crystallizing catalytically active
enzyme with peptide substrates. Our strategy has been to analyze structures of active PR
with substrate analogs, while other groups have used an alternative strategy of
crystallizing an inactive enzyme with peptide substrates. Crystal structures have been
reported of the inactive PR variant (PRD25N) in complex with peptides representing the
MA-CA, CA-p2, p2-NC, NC-p1, p1-p6, p2-NC, RT-RH and RH-IN cleavage sites, and
inactive mutant PRV82A/D25N with MA-CA, CA-p2, NC-p1 and p1-p6 peptides (PrabuJeyabalan et al. 2002; Prabu-Jeyabalan et al. 2003; Prabu-Jeyabalan et al. 2004). These
inactive complexes were refined at about 1.9 Å resolution or lower. We have reported
crystal structures of PR, single mutants in complex with substrate analogs CA-p2 and p2NC (PRD30N, PRK45I, PRN88D and PRL90M), and double mutants with CA-p2 (PRK45I/V82S,
PRK45I/L90M, PRD30N/V82S and PRN88D/L90M) at resolutions ranging from 2.2 to 1.2 Å (Weber
et al. 1997; Mahalingam et al. 2001; Mahalingam et al. 2002). Reduced peptide analogs
mimic the transition state of the hydrolytic reaction since they contain an amine and
tetrahedral carbon at the non-hydrolyzable peptide bond. A complete set of accurate high
resolution structures of active PR with different substrate analogs will more accurately
reflect the structures of reaction intermediates. Therefore, high resolution crystal
structures of PR and the common drug resistant variants PRV82A and PRI84V were
determined with reduced peptide analogs that represent the CA-p2, p2-NC, p6pol-PR and
p1-p6 polyprotein cleavage sites. These structures and kinetic data provide details of the
PR interaction with reaction intermediates and better understanding of the substrate
specificity. Comparison of protease complexes with clinical inhibitors has improved our
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knowledge of the molecular basis of drug resistance and will assist in the structure-based
design of more potent anti-viral inhibitors.

Aim 2: To determine & analysis crystal structures of PR and mutants PRV82A,
PRI84V, PRD30N and PRI50V with UIC-94017
Most current PIs were designed based on substrate peptides, so they generally are
targeted on wild type PR and have enhanced hydrophobic groups on the side chains and
high molecular weight. Novel inhibitors that target critical conserved regions of the PR
different from those of the current drugs are expected to be more active against resistant
variants of HIV-1 PR. A novel non-peptide inhibitor UIC-94017 (also called TMC-114)
has been developed that is extremely potent in vivo against a wide spectrum of HIV
strains including multi-drug resistant clinical strains, with the IC50 values of 3-29 nM for
the inhibition of the PR mutants selected for resistance to saquinavir, indinavir,
nelfinavir, or ritonavir (Koh et al. 2003; Surleraux et al. 2005). This promising nonpeptidic inhibitor is in Phase III clinical trials and shows superiority to the approved
clinical PIs (Shurtleff 2004). This compound is chemically related to the clinical inhibitor
amprenavir, and was designed with a novel bis-tetrahydrofuranylurethane (bis-THF)
group to incorporate additional polar interactions with main chain atoms of the PR dimer.
UIC-94017 was observed to bind to the PR with favorable change in enthalpy with ∆H of
12.1 kcal/mol (King et al. 2004), whereas other PIs, such as indinavir, nelfinavir, and
saquinavir, their binding is an enthalpically unfavorable process with ∆H small or even
negative (Velazquez-Campoy et al. 2000; Velazquez-Campoy et al. 2001). Alternatively,
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the favorable entropy gain by the desolvation of big hydrophobic side chains upon
binding for most of the PIs in clinical use compensates for the lack of the favorable
enthalpy change. Therefore, it suggests that most PIs have very few attractive interactions
when bound to the PR, and changes in the geometry of the cavity due to mutations in the
binding site may result in considerable loss of the PI’s affinity to the PR. Crystal
structures of complexes of the UIC-94017 with PR and four common drug resistant
mutants PRV82A, PRI84V, PRD30N and PRI50V have been determined at high resolution to
understand the molecular basis for the potency of this compound. Such structures are
also beneficial in predicting which active site mutations may generate resistant HIV.
Furthermore, a complete set of kinetic data of UIC-94017 with comparison to indinavir
under same conditions will assist the evaluation of these structure-based designed
compounds and help to understand the role of drug resistance.

Aim 3: To determine & analysis crystal structures of PR and mutants PRV82A and
PRI84V with saquinavir.
Saquinavir (Figure 1.6), one of the eight protease inhibitors proved by FDA, is a
peptide-like substrate analog that binds to the protease active site and inhibits the activity
of the enzyme. This inhibition prevents the cleavage of the viral poly-proteins and results
in the formation of immature noninfectious virus particles. Saquinavir was first
introduced in 1995 (FDA 2005). Saquinavir has been shown to inhibit HIV activity in
both acutely and chronically infected cells with EC50 values in the range of 1 to 30 nM
(Craig et al. 1991). Combinations of saquinavir with other protease inhibitors, such as
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amprenavir, atazanavir, or lopinavir resulted in synergistic antiviral activity. In cell
culture, saquinavir also exhibited additive to synergistic effects against HIV-1 when
using with reverse transcriptase inhibitors without enhanced cytotoxicity (Deminie et al.
1996). However, similar to other PIs, the long-term therapeutic efficiency is limited by
the rapid development of drug resistant mutants with reduced susceptibility to saquinavir
(Ji and Leob, 1992; Ho et al., 1995; Wei et al., 1995). Genotypic analysis of HIV-1
isolates with reduced susceptibility to saquinavir identified resistance conferring primary
mutations G48V and L90M in the protease gene, and secondary mutations L10I/R/V,
I54V/L, A71L/T, G73S, V77I, V82A and I84V that contributed additional resistance to
saquinavir (Jacobsen et al. 1995; Boucher 1996; Jacobsen et al. 1996). The degree of
reduction in susceptibility to saquinavir of clinical isolates bearing substitutions G48V
and L90M depends on the number of secondary mutations present. In general, higher
levels of resistance are associated with greater number of mutations only in association
with either or both of the primary mutations G48V and L90M (Boucher 1996).
Nevertheless, little structural study has been done on this inhibitor, only a few structures
(PR (Krohn et al. 1991), PRD25N/V82A (Prabu-Jeyabalan et al. 2003), PRG48V/L90M (Hong et
al. 2000), 9X mutant structure (Munshi et al. 2000)) are available and they are all around
2.5 Å resolution. Here, the kinetic data and atomic resolution structures of wild-type,
PRV82A and PRI84V in complex with saquinavir were studied. PRV82A/SQV structure was
refined at 0.97 Å resolution, which is by far the highest resolution structure for this
complex. As mentioned before, V82A and I84V are two particularly important mutants
which are observed to have cross-resistance. They are associated with high level drug
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resistance for almost all seven available PIs (Figure 1.7). Thus the structures presented
here will give the detail molecular based information to help understand the drug
resistance to saquinavir and provide valuable reference to compare with other PI drugs.
The comparison will help understand the structural advantage and disadvantage of
compounds and further help the design of more efficient next generation inhibitors.

Aim 4: To develop a small database for organizing and automating the analysis of
protease-inhibitor structures.
Although great efforts have been made to study of HIV-1 protease, only a small
number of databases have been developed to summarize these valuable data about
sequence, resistance, immunology, and vaccine trials information. These databases are
available online, such as Los Alamos HIV PR databases at http://hivweb.lanl.gov/content/index, Stanford HIV PR sequence and resistance databases at
http://hivdb.stanford.edu and the National Institute of Allergy and Infectious Disease site
of anti-HIV compounds at http://www.niaid.nih.gov/daids/dtpdb. A HIV PR structural
database containing about 200 structures is also available at National Institute of
Standards and Technology (NIST) site at http://srdata.nist.gov/hivdb. This database not
only provides certain descriptive information, for example, cell parameters, space group
and citations, but also puts great emphasis on the study of the inhibitors. The best aspect
is that it provides a tree of fragments within the selected inhibitor and allows a further
tool to perform fragment searches on the inhibitor. Using this tool a user may rapidly
search for multiple fragments and thus perform homology searches. However, there are
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some limitations. One is that it is a website based program, so, although it offers broad
information it is not designed for local lab use and is not secured for those unpublished
data. Besides, it focuses less on the structural study, for example, no tools are available to
analyze the detailed interactions between atoms or superimpose different complexes. For
this instance, and as more and more structures of different HIV-1 protease complexes
(>50) will soon be completed in our lab and overall hundreds of HIV protease structures
have been published, a database which can be incorporated with some analytical
programs as well as present more efficient management would be beneficial. There are at
least two reasons for creating this database. First, as only a few inhibitors have reached
approval by the FDA as anti-AIDS drugs, we are working on a lot of those compounds
still being synthesized or under development by Dr. Arun Ghosh’s lab. The information
about these compounds is valuable and confidential. Some of them may not have direct
clinical significance but still be important for the purpose of design. Second, the database
would provide an efficient way to analysis and compare ligand-enzyme interactions in the
structures and provide useful information that could help exploring new drug-design
principles and synthetic strategies. Its shell will contain structural files that have been
previously deposited in the Protein Data Bank (PDB) or can be directly uploaded into the
HIV PR database. After filtering by protease or inhibitor name (decided by the user), the
files of complexes are placed in a list. A branched link can display the pdb file and the
3D structure can be visualized by Rasmol (Kohl et al. 1988). At this stage, the analytical
part of the database consists of two basic functions: distance calculation and
superimposing program FUD. For distance calculation, the residues (or atoms) and the
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range of distance to be calculated can be defined by the user and be applied to multiple
structural files. Whilst for superimposing structures, a maximum of eight structures can
be superimposed on the same reference file at the same time. A plot of the RMS
deviations on Cα against each residue will be shown, with the global RMS deviation for
each pair of comparison presented at the top. Later on, more calculations or analytical
programs can be incorporated easily for further development.
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2. Methods
2.1 Protein expression and purification
The HIV-1 PR has been optimized for structural and kinetic studies, with 5
mutations: Q7K, L33I, L63I to minimize the autoproteolysis of the PR, and C67A and
C95A to prevent cysteine-thiol oxidation (Wondrak et al. 1996). The construction and
expression of HIV-1 PR, PRD30N, PRI50V, PRV82A and PRI84V was carried out as described
(Louis et al. 1989; Wlodawer et al. 1993). Mutations were confirmed by protein mass
spectrometry. The purification and refolding procedures were similar to those used by
(Louis et al. 1989; Wondrak et al. 1996).
Escherichia coli cells with PR constructs were incubated in 2 L LB (Luria
Bertani) broth containing 100 µg/ml carbenicillin and 1% glucose at 37 ˚C. After A600
reached 0.5-0.6, the cells were induced by IPTG (2mM) for around 4 hours. After
pelleted by centrifuge (4,000 rpm, 20 min, 4 ˚C), the cells were suspended in 20 volumes
of TE buffer (50 mM Tris-HCl, 10 mM EDTA, pH 8.2) and add to it 0.1 mg/ml
lysozyme. After sitting on ice for 10 min, the cells were lysed by sonication at 4 ˚C for 10
min with 1 min pulses at 1 min intervals. The inclusion bodies (IB) were clarified by
centrifugation at 12,000 rpm for 20 min at 4 ˚C. The IB pellet was then suspended in TE
buffer with 1% triton X-100 and 2 M urea. After centrifuge at 12,000 rpm for 20 min at 4
˚C, the pellet was washed by TE buffer and dissolved in 3 volumes of TE buffer
containing 8 M urea and 10 mM DTT. The supernatant was subjected to gel filtration
chromatography on Superdex 75 (HiLoad 26/60, Pharmacia Biotech, Uppsala, Sweden)
with elution buffer (50 mM Tris-HCl (pH 8.2), 4 M guanidine hydrochloride and 5 mM
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EDTA) at a flow rate of 1 ml/min. The proteins in the peak fractions around 135 ml were
collected and further purified by HPLC with RPC-15 column (reverse phase) (ST
4.6/100, Amersham Biosciences) using a gradient of 0 to 100% acetonitrile with 0.05%
trifluoroacetic acid at a flow rate of 2 ml/min. The major peak corresponding to HIV-1
protease eluted at 40% acetonitrile. The presence of protein was confirmed by SDSPAGE. The desired HPLC fractions were dialyzed against 200 volumes of first, 25 mM
formic acid and then, 50 mM sodium acetate (pH 5.0) at 4 ˚C to obtain folded active
protease.

2.2 Substrates, peptide analogs and small organic inhibitors
The chromogenic substrate L6525 was purchased from Sigma. Two series of
inhibitors, substrate analogs and small organic molecules, were used to grow crystals
with wild-type protease and mutants (details shown in Table 2.1 and Figure 2.1). CA-p2
and p2-NC reduced peptide analogs were purchased from BACHEM. The NC-p1, p1-p6
and p6pol-PR reduced peptides and the substrate for fluorescence essay were synthesized
by Dr. Ivo Blaha (Ferring Leciva, Prague). The substrate analog inhibitors were
dissolved in deionized water by vortexing for several minutes, and then centrifuged
briefly to remove any insoluble material. The small organic inhibitors were dissolved in
dimethyl sulfoxide (DMSO). UIC-94017 was designed and synthesized by our
collaborator Dr. Arun Ghosh’s group.
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Table 2.1 Substrate analogs.

O

Cleavage site

Number

Sequence

CA-p2

N1270

R-V-L-r-F-E-A-Nle

p2-NC

N1465

Ac-T-I-Nle-r-Nle-Q-R

NC-p1

IB 308

E-R-Q-A-N-r-F-L-G-K-I

p1-p6

IB 307

R-P-G-N-F-r-L-Q-S-P

p6-PR

IB 306

V-S-F-N-F-r-P-Q-I-T-K-K

H
N

O
O

O

OH

R2
O

N

S
O

R1

Figure 2.1 Backbone structure of small organic compounds.
(A series of compounds designed and synthesized by Dr. Arun Ghosh)

R3
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2.3 Crystallization and data collection
The refolded PR or mutant was concentrated to 3 to 5 mg/ml, and mixed with the
substrate analog inhibitor at a 20-fold molar excess (2- fold for synthesized small
inhibitions). The mixture was incubated at 4 ˚C for an hour and then centrifuged.
Crystallization was achieved by the hanging-drop vapor-diffusion method at 297 K using
24-well VDX plates (Hampton Research). Equal volumes of enzyme-inhibitor stock and
reservoir solution were used. The screening was performed with combinations of the
following solutions: 0.1 M sodium acetate buffer, pH from 4.2 to 5.0, 0.1 M citrate
phosphate buffer, pH from 5.0 to 6.4, 5% DMSO, 0 to 5% dioxane, 0.4 M to 1.2 M
sodium chloride and 15% to 40% saturated ammonium sulfate (crystal pictures are shown
in Figure 2.2). Generally, the kind of salt used in crystallization will not affect the space
group of the crystal. Except for PRV82A/SQV and PRI84V/SQV complex, crystals in space
group P212121 were obtained with ammonium sulfate as precipitant, while crystals with
space group P21212 grew from sodium chloride.
The crystals were frozen in liquid nitrogen using glycerol as a cryoprotectant,
which was added to the reservoir solution to a final concentration of 30% (v/v). X-ray
diffraction data were collected at National Synchrotron Light Source, beamline X26C or
Advanced Photon Source, beamline SER-CAT 22. An example of diffraction pattern of
HIV-1 protease is shown in Figure 2.3.
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A.

B.

C.

D.

E.

F.

Figure 2.2 Crystal pictures of some complexes.
A. B. C. crystals for substrate analogs; D. crystal for PRV82A/UIC-94017; E. crystals for
PRV82A/Saquniavir (space group P212121); F. crystal for PRV82A/Saquniavir (space group
P21212)
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Figure 2.3 Example of a diffraction pattern of HIV-1 protease.
The dark spots are called reflections. The reflection spots are those X-rays that are
diffracted after traveling through a crystal. The white shadow at the center of the image is
produced by a beamstop which is used to block high energy X-rays from directly hitting
the image plate detector to protect the detector.
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2.4 Data processing and refinement
The datasets collected at the National Synchrotron Light Source were processed
using the HKL suite 1.96, and the other datasets collected at the Advanced Photon Source
were processed by HKL 2000 package (Otwinowski et al. 1997). Molecule replacement
was done using AMoRe (Navaza 1994). The starting model for molecular replacement
was chosen from the highest resolution structure available at the moment. The structures
were refined using the program SHELXL (Sheldrick et al. 1997), and map display and
refitting used the molecular graphics program O (Jones et al. 1991). Structure solution in
the P21 space group was tested when the structures showed two alternate conformations
of inhibitor in P212121. Alternate conformations for PR residues, water and other solvent
molecules were modeled when observed. The type of ion and other solvent molecules
were identified by the shape of the 2Fo-Fc electron density map, the potential for
hydrogen bonding, the coordination state, and inter-atomic distances, for molecules
present in the crystallization conditions. Anisotropic B factors were applied. Hydrogen
atoms were calculated in the last round of refinement by SHELXL (except for p6pol-PR
complexes which had low resolution of 1.42 and 1.6 Å).
Structures were compared by superimposing their main chain atoms using the
algorithm described in (Mahalingam et al. 2004). Distances between atoms were
calculated. Two atoms with separation of about 4 Å (3.85 Å is the average) are
considered to form van der Waals interactions, while those of 2.6 to 3.2 Å (2.85 Å is the
average) in distance and between a hydrogen bond donor atom and a hydrogen bond
acceptor atom are hydrogen bonds. To analysis more accurately and efficiently, a small
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database incorporated with basic structural analysis functions was designed to automate
this process. The database interface was programmed by JAVA language (Sun
Microsystems, Inc.). Structural figures were made using Molscript (Kraulis 1991),
Bobscript (Esnouf 1997; Esnouf 1999) and Weblab viewer (Molecular Simulations Inc.).
All structures and diffraction data were deposited to the PDB (Berman et al. 2000). The
PDB codes are listed in Appendix 1.

2.5 Kinetic measurements
The kinetic parameters, inhibition constant Ki, for peptide analogs of the CA-p2,
p2-NC, p6pol-PR and p1-p6 natural PR cleavage sites, and the catalytic efficiency kcat/Km
were measured by UV spectroscopic assay with the chromogenic substrate (Lys-Ala-ArgVal-Nle-p-nitroPhe-Glu-Ala-Nle-amide, L6525, Sigma), which is an analog of the CA-p2
cleavage site. The assay solution contained 50mM sodium acetate, pH 5.0, 0.1 M NaCl,
1mM EDTA. The reaction concentrations of enzyme and the substrate were 70 to 120
nM and 300 µM, respectively. The PR concentrations were determined by active site
titrations with indinavir and the substrate concentration was determined by converting
absorbance of the substrate to concentration via a calibration curve. The decrease in
absorbance at 310 nm of the reaction mixture was measured on a Hitachi U-2000
spectrophotometer. Michaelis-Menten curves over 25-400 µM substrate and the
inhibition curves were fit by SigmaPlot 8.0.2 (SPSS Inc.). Inhibition constants of each
analog inhibitor were obtained from the IC50 values estimated from a dose-response curve
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using the equation Ki = (IC50 – 0.5*[E])/(1+[S]/Km), where [E] and [S] are the PR and
substrate concentrations, respectively.
Kinetic parameters for small chemical inhibitors were determined by a
fluorescence assay as described (Bagossi et al. 2004). A synthetic peptide,
RE(Edans)SQNY-PIVRK(Dabcyl)R (Matayoshi et al. 1990; Wang et al. 1990) based on
the HIV-1 MA-CA cleavage site in the Gag-Pol polyprotein was used. Protease 10 µl
(final concentration of 7-12 nM) was mixed with 100 µl PNF buffer (250mM phosphate
buffer, pH = 5.6 containing 500 mM NaCl, 1mM EDTA, 5 mM DTT and 5% glycerol)
and pre-incubated at 37 oC for 5 min. The reaction was initiated by adding 90 µl
substrate (final concentration of 2-40 µM). The mixture was assayed over 5 min for the
increase in fluorescence, which was detected at 460 nm, using 355 nm excitation
wavelength in a POLARstar OPTIMA fluorimeter-luminometer (BMG Labtechnologies
Inc.). Inhibition assays were performed in the same way, but the reaction mixture
contained 2 µl DMSO or inhibitor dissolved in DMSO. Inner filter effect was determined
by measuring the fluorescence as a function of the concentration of RE (Edans), at the
substrate concentration range used for the kinetic measurements. Data analysis was
performed same way as discussed for the UV spectroscopic assay.
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3. Results and discussion
3.1 Structural analysis of complexes with substrate analogs
Specific aim: To determine & analysis crystal structures of PR and mutants PRV82A
and PRI84V with peptide analogs.
High resolution (1.1 – 1.6 Å) crystal structures of PR and the common drug
resistant variants PRV82A and PRI84V were determined with reduced peptide analogs that
represent the CA-p2, p2-NC, p6pol-PR and p1-p6 polyprotein cleavage sites. These
structures and kinetic data provide details of the PR interaction with reaction
intermediates and better understanding of the substrate specificity. Furthermore,
comparison of substrate analog complexes with clinical inhibitors has improved our
knowledge of the molecular basis of drug resistance and will assist in the structure-based
design of more potent anti-viral inhibitors.

Inhibition of PR, PRV82A and PRI84V
The reduced peptide analogs represented five different HIV-1 cleavage sites
(Table 3.1.1). The p2-NC site is the first and CA-p2 the last in sequential processing of
Gag precursor (Pettit et al. 1994). Cleavage of p6pol-PR is essential for release of mature
active protease (Louis et al. 1994). Mutations in the NC-p1 and p1-p6 sites contribute to
drug resistance both in vitro and in vivo (Croteau et al. 1997; Zhang et al. 1997; Robinson
et al. 2000). These two cleavage sites show significant sequence polymorphism (Barrie
et al. 1996; Bally et al. 2000), and the specificity of cleavage has been studied with PR
and several mutants (Feher et al. 2002). The peptide analogs differed in length. CA-p2

Table 3.1.1 Sequence of the substrate analog inhibitors and inhibition constants.
Values are listed for Ki (µM) and (Ki relative to PR).
Cleavage Site

Peptide Sequence

PR

PRV82A

PRI84V

CA-p2

R-V-L-r-F-E-A-Nle

0.075 ± 0.009

0.024 ± 0.004 (0.3)

0.275 ± 0.031 (3.7)

p2-NC

Ace-T-I-Nle-r-Nle-Q-R

2.17 ± 0.28

0.53 ± 0.078 (0.24)

13.0 ± 1.5 (6.0)

p6pol-PR

V-S-F-N-F-r-P-Q-I-T-K-K

22.1 ± 2.8

36.3 ± 5.4 (1.6)

46.6 ± 5.3 (2.1)

p1-p6

R-P-G-N-F-r-L-Q-S-R-P

96.7 ± 12.3

28.2 ± 4.2 (0.3)

> 500 (>5)

NC-p1

E-R-Q-A-N-r-F-L-G-K-I

> 500

> 500

> 500
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and p2-NC were the two shortest peptides, extending from P3 to P4’ and P3 to P3’,
respectively. The analogs NC-p1 and p1-p6 extended from P5 to P5’, while p6pol-PR
extended from P5 to P6’ since lysine was added to provide greater solubility.
The catalytic activities of PR and the mutants PRV82A and PRI84V were
competitively inhibited by the five substrate analogs (Table 3.1.1). Previous studies
demonstrated that reduced peptide bond-containing inhibitors act in a competitive manner
on HIV-1 PR, and the same type of inhibition was assumed in this study for the mutants
(Tozser et al. 1991a). The inhibition constants for PR were in the order CA-p2 < p2-NC
< p6pol-PR < p1-p6 < NC-p1. The CA-p2 analog was the best inhibitor of PR and the
mutants, while the NC-p1 analog was the weakest inhibitor for all enzymes with Ki > 500
µM. PRV82A was better inhibited than PR (about 3-fold) by all the analogs, except for
p6pol-PR. PRI84V was poorly inhibited relative to PR for all analogs with 2 to 6-fold
higher Ki values. This variation in Ki was smaller than observed for the clinical
inhibitors that showed 2 to 11-fold relative inhibition of the mutants PRV82A or PRI84V
compared to wild type PR (Klabe et al. 1998).

Description of the high resolution crystal structures
Eight crystal structures have been determined of PR and drug resistant mutants
PRV82A and PRI84V in the complexes with four different substrate analogs.
Crystallographic statistics are summarized in Table 3.1.2. Seven of these are new
structures, while PR/CA-p2 complex was determined at the higher resolution of 1.4 Å
compared to 1.9 Å for the previously reported structure (Mahalingam et al. 2001).

Table 3.1.2 Crystallographic data statistics.
Protease
Inhibitor
Space group
Unit cell
dimensions
(Å)

a
b
c
Resolution range (Å)
Unique reflections
Rmerge (%)
Overall (final shell)
<I/sigma>
Overall (final shell)
Data range for refinement (Å)
Rwork (%)
Rfree (%)
No. of waters (total occupancies)
Completeness (%)
Overall (final shell)
RMS deviation from ideality
Bonds (Å)
Angle distance (Å)
Average B-factors (Å2)
Main chain
Side chain
Inhibitor
Solvent

*PRV82A
CA-p2
P21212
57.89
85.96
46.19
50-1.54
34544
6.5
(37.1)
13.4
(5.8)
10-1.54
0.12
0.19
194
99.6
(100)

*PR
p2-NC
P21212
58.00
85.78
46.53
50-1.40
44291
10.1
(45.6)
8.9
(2.1)
10-1.40
0.15
0.19
188
95.6
(66.6)

*PRV82A
p2-NC
P21212
58.02
85.89
46.61
50-1.10
95318
10.2
(37.7)
10.4
(2.1)
10-1.10
0.13
0.17
206
94.8
(68.4)

PRI84V
p2-NC
P21212
57.80
85.59
46.46
50-1.30
55009
7.9
(33.0)
14.4
(3.2)
10-1.30
0.12
0.16
223.5
96.0
(72.4)

#

PR
p6pol-PR
P21212
59.45
87.00
46.32
50-1.60
32005
9.1
(41.3)
13.2
(3.7)
10-1.60
0.15
0.23
155
99.2
(93.1)

#

PRV82A
p6pol-PR
P21212
58.88
86.27
46.40
50-1.42
40847
9.8
(70.8)
17.1
(2.6)
10-1.42
0.18
0.23
199
90.3
(100)

*PR
p1-p6
P21212
58.91
86.07
46.54
50-1.38
47418
10.4
(28.6)
14.1
(13.8)
10-1.38
0.16
0.21
190
89.2
(96.2)

PRV82A
p1-p6
P21212
58.46
85.85
46.39
50-1.32
55317
8.4
(57.7)
10.4
(2.9)
10-1.32
0.13
0.18
297
99.9
(100)

0.010
0.029

0.011
0.029

0.015
0.033

0.013
0.030

0.009
0.029

0.011
0.031

0.010
0.030

0.012
0.034

15.9
21.9
27.5
31.5

8.0
12.2
14.0
23.7

9.0
13.7
10.6
24.4

10.6
15.4
14.7
25.8

22.4
27.6
29.9
37.9

16.7
21.1
19.1
30.9

14.2
18.4
18.3
27.3

12.0
17.0
24.0
26.7

*: Diffraction data collected at Advanced Photon Source, beamline SER-CAT 22. All other data were collected at National Synchrotron Light Source,
beamline X26C. #: Structures in which hydrogen atoms were not added.
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Crystals and diffraction data were obtained for PR with the NC-p1 analog; however, the
electron density was disordered and not interpretable for the analog probably due to weak
binding and consistent with the high Ki values of >500 µM. The asymmetric unit of the
crystals contained a PR dimer with the residues in the two subunits numbered 1-99 and
1’-99’. All structures are in space group P21212 and were refined to R-factors of 0.120.18 including solvent molecules, and anisotropic B-factors. The resolution ranges from
1.10-1.60 Å. The complex PRV82A/p2-NC was determined at 1.1 Å resolution, which is
the highest resolution to date for a substrate analog complex. The quality of the electron
density map is shown in Figure 3.1.1. These crystal structures showed clear electron
density for all the protease atoms, P4-P4’ residues in the peptide analog, and solvent
molecules. All the peptide analogs, except for p2-NC, showed two pseudosymmetric
conformations bound to both subunits of the PR dimer. The p6pol-PR and p1-p6 analogs
have 11 and 10 residues, respectively, compared to 6-7 for the CA-p2 and p2-NC
analogs. The longer analogs extended out of the PR binding pocket, and showed poor
electron density at both termini. The average B-factors ranged from 8.0 to 22.4 Å2 for
protein main chain atoms and 10.6 to 29.9 Å2 for protein side chain and inhibitor atoms.
The lower average B-factors were observed for the higher resolution structures.
Alternate conformations were modeled for the side chain atoms of about 30
residues in all the crystal structures based on the shape of the electron density (Figure
3.1.2). Only Lys 7 had alternate conformations in both subunits of all structures, while
Met 46 had alternate conformations in all but one subunit. Most of these alternate
conformations were observed for residues with longer and flexible side chains, such as
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A.

B.

Figure 3.1.1 Electron density map for PRV82A/p2-NC crystal structure.
The 2Fo−Fc map was contoured at a level of 2.2 .
A. Residues 78-82.
B. Asp 30 interacting with P2’ Gln.

Figure 3.1.2 Statistics of the residues with alternate conformations.
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Lys and Glu, while alternate conformations were observed also for hydrophobic residues
including Leu, Ile and Val. The number of alternate conformations was in the order of
Lys (68 with alternate conformations), Ile (41), Glu (35), Met (15), followed by Gln, Arg,
Ser and Leu at about 10 each. Some residues including 33’, 34’ and 35’ were observed to
have two conformations only in one subunit of the dimer. These residues were located on
the surface of structure so they are either very flexible or involved in interactions with
symmetry related molecules. The presence of alternate conformations of side chains for
Leu 23, Lys 45/45’, Met 46/46’, Ile 50/50’, Val 82/82’ and Ile 84/84’ in the inhibitor
binding site was consistent with previous descriptions (Mahalingam et al. 2001; Tie et al.
2004). Alternate positions with a 180 degree flip of the main chain atoms of Ile 50 and
50’ were observed in complexes PR/p1-p6, PRV82A/p1-p6, PR/p6pol-PR and PRV82A/p6polPR, as described for the PR structures with the potent antiviral inhibitor UIC-94017 (Tie
et al. 2004).

Overall comparison of the crystal structures
All the PR dimers shared very similar backbone structures with RMS (root-meansquare) deviation for all Cα atoms ranging from 0.09 to 0.26 Å compared to the PR/p2NC complex. The least variation was observed for the complexes with p2-NC. The
deviations for residues in subunit A (within 1 Å) were larger than those of subunit B
(within 0.8 Å). Larger deviations for all the structures were located at external loop
residues 38 to 41 and residues 79-84 near the mutations. The biggest difference from
PR/p2-NC was observed for the complexes with p6pol-PR analog, and occurred at
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residues 47 to 53 in the hairpin loop that links two β-strands in the flap in both subunits.
Residues 25 to 28 at the active site had the least deviation in both subunits for all
structures.

Protease interactions with substrate analogs
This series of high resolution crystal structures allowed more precise description
of the PR interactions with transition state mimics. Important conserved features of the
PR interaction with substrate analogs of size P4-P4’ have been identified from crystal
structures (Gustchina et al. 1994; Mahalingam et al. 2001). These new structures can
extend the description of the interactions to more distal residues with greater accuracy.
Peptide analogs are bound with each side chain from P5 to P5’ lying within a set of
subsites S5 to S5’ formed by PR residues. Figure 3.1.3 shows the superimposed substrate
analogs in the PRV82A complexes. The P2-P2’ side chains were in similar positions while
the more distal residues had greater conformational variation. PR recognizes substrates
by means of a series of hydrogen bond interactions with the main chain atoms of the
peptide (Figure 3.1.4). All the structures showed similar hydrogen bond interactions
between PR and inhibitor in P3-P3’ positions, while there was more variation at the distal
ends. Two water molecules are conserved in all eight structures and mediate the
interactions between PR and inhibitor. One conserved water lies between the flap region
(Ile 50 and 50’) and P2 and P1’ of inhibitor, which has been proved to be important for
catalysis (Grzesiek et al. 1994; Wang et al. 1996), the other mediates interactions of P2’
with Gly 27’ and Asp 29’.
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Figure 3.1.3 Superposition of four PRV82A complexes with CA-p2, p2-NC, p6pol-PR
and p1-p6.
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A.

B.
Figure 3.1.4 Hydrogen bond interactions between protein and inhibitor.
Hydrogen bond interactions are considered for interatomic distances of 2.5-3.3 Å. Water
molecules are indicated by red spheres. Water-mediated hydrogen bonds are shown in red
dashed lines, while direct interactions between protease and inhibitor are in black.
A. Hydrogen bond interactions between PRV82A and CA-p2. (One water-mediated
interaction between P3Arg and Pro 81’ is not shown.)
B. Hydrogen bond interactions between PR and p2-NC. (Water-mediated interactions
of both termini of inhibitor with Arg 8 and 8’ are not shown.)
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C.

D.
Figure 3.1.4 Hydrogen bond interactions between protein and inhibitor.
C. Hydrogen bond interactions between PR and p6pol-PR. (Water-mediated
interactions of C termini of p6pol-PR with Asp 60 and Gln 61 are not shown.)
D. Hydrogen bond interactions between PRV82A and p1-p6. (Water-mediated
interactions of C termini of p1-p6 with Trp 6, Arg 8 and Arg 87’ are not shown.)
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Complex with CA-p2 analog
The CA-p2 analog was bound to PRV82A in two orientations with relative
occupancy of 0.65/0.35. The complex structure was similar to the structure of PR/p2-NC
with RMS deviation on alpha carbon atoms of 0.20 Å. Residues P3-P4’ of CA-p2
interacted with PR (Figure 3.1.4A). Compared to p2-NC, the CA-p2 analog lacked an
acetyl group at P4 and cannot form the same van der Waals interactions with PR.
However, the CA-p2 analog with P2’ Glu had two proton-mediated hydrogen bond
interactions with the Asp 30 carboxylate side chain, instead of the single hydrogen bond
of P2’ Gln in p2-NC (Figure 3.1.1B), as observed previously (Mahalingam et al. 2001).
The Nle at P4’ position in CA-p2, instead of the NH2 in p2-NC, allowed formation of
hydrogen bonds with the carbonyl oxygen of Met 46’ and the side chain of Lys 45’.
Furthermore, P3 is Arg in CA-p2 and Thr in p2-NC. As a result, the carbonyl oxygen of
P3 Arg interacted with the amide of Asp 29 instead of the interaction of the amide of P3
Thr with carbonyl oxygen of Gly 48 in the flap. Also, the longer side chain of Arg
provided more van der Waals interactions with the PR. These differences agreed with the
25-fold stronger inhibition observed for the analog CA-p2 compared to p2-NC.

Structural comparison of the complexes with p2-NC analog
Crystal structures were determined of complexes of the substrate analog p2-NC
with PR and the two mutants PRV82A and PRI84V. The p2-NC showed one conformation in
all three protease complexes. The interactions between PR and analog extended to P4P4’ with the P4 acetyl group and there was clear density for all the residues. All three
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structures were very similar with RMS deviation of 0.09 and 0.11 Å for PRI84V and
PRV82A, respectively. There were conserved hydrogen bond interactions with main chain
amide and oxygen atoms extending from P3 O to P4’ N, and the P2’ Gln side chain
formed hydrogen bond interactions with Asp 29’ and Asp 30’ in all three structures
(Figure 3.1.4B). Multiple conformations were modeled for the side chain of P1’ Nle
depending on the shape of the electron density in the complexes with mutants. The main
chain oxygen of P3 Thr had water mediated interactions with Gly 27 and Asp 29.
Moreover, the hydroxyl oxygen of P3 Thr interacted with Asp 30 via a water molecule.
These two waters may stabilize the protease inhibitor interactions, as suggested
previously (Mahalingam et al. 2001).
There were small compensating changes in the interactions with p2-NC in the
complexes with PRV82A and PR. P3’ in PRV82A/p2-NC showed more interactions with
water molecules than observed in PR complex. Alternatively, it is possible that more
water molecules were identified due to the higher resolution of the PRV82A/p2-NC
complex. In mutant PRV82A, Ala 82 had lost the van der Waals interaction with P4 Ace,
and had weaker interactions with P1 (interatomic distances were longer than 4 Å).
However, the interactions at P1’and P3’ were enhanced (Figure 3.1.5A) mainly by the
shifts of the side chains of P1 Nle and P3’ Arg and partially by the small (0.3 Å) shift of
the CA atom of Ala 82/82’. The side chain of P1’ Nle showed three orientations which
formed closer contacts with the CB atom of Ala 82 in PRV82A than observed with Val 82
in PR. The CE atom of P3’ Arg moved about 1.2 Å and formed closer interactions with
CB atom of Ala 82. All these observed structural changes and closer van der Waals
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A

B.
Figure 3.1.5 Structural variation around residues 81 84 in p2-NC, p6pol-PR, p1-p6,
UIC-94017 and indinavir complexes.
The PR structure is in purple, PRI84V in green and PRV82A in blue bonds. Interatomic
distances (Å) are indicated by dashed lines.
A. PRV82A/p2-NC superimposed on PR/p2-NC.
B. PRI84V/p2-NC superimposed on PR/p2-NC.
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interactions with p2-NC were consistent with 4-fold better inhibition for PRV82A than PR
(Table 3.1.1). Small changes in the backbone atoms of residue 82 in mutant PRV82A in
complex with non-peptidic inhibitors, have been described (Baldwin et al. 1995).
PRI84V/p2-NC had lost some interactions with p2-NC due to the mutation. Val 84
in PRI84V/p2-NC had fewer interactions with P2, compared to those of Ile 84 in the
PR/p2-NC structure. Similar to the PRV82A complex, the flexibility of P1’Nle side chain
had compensated partially for the loss of van der Waals interactions caused by shortening
the side chain from Ile to Val (Figure 3.1.5B). These changes also agreed with the 6-fold
worse inhibition of p2-NC for PRI84V than PR. These observations suggested that analog
p2-NC modulated the binding affinity for mutants through small conformational changes
of the side chain of P1’ Nle. Similarly, the conformational flexibility of the Met side
chain in the natural substrate is expected to compensate for the drug resistant mutations
like V82A and I84V.

Structural comparison of the complexes with p6pol-PR analog
The two structures of PR and PRV82A with p6pol-PR analog were very similar with
RMS deviation on alpha carbon atoms of 0.17 Å, and were similar to PR/p2-NC structure
with RMS deviation values of about 0.25 Å. The p6pol-PR showed alternative
conformations with relative occupancies of 0.6/0.4 and 0.8/0.2 for PR and PRV82A,
respectively. Since the p6pol-PR analog had eleven residues and extended out of the PR
binding pocket, both N and C terminal residues were quite flexible with poor electron
density. Due to the absence of electron density for the side chain at the C-terminus Ala
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was modeled instead of P6’ Lys. On the other hand, the longer peptide provided
interactions extending from P5 to P5’as illustrated in Figure 3.1.4C. P2 is the polar Asn,
unlike the hydrophobic Val and Ile in CA-p2 and p2-NC. Hence, the side chain of P2 Asn
formed hydrogen bonds with Asp 29 and Asp 30, which cannot occur in CA-p2 or p2NC. The p6pol-PR had the larger hydrophobic Phe at P3 compared to Arg, Thr or Gly in
the other analogs. Therefore, P3 Phe occupied more space in the binding pocket, and
fewer water-intermediated interactions were observed. The smaller amino acid Pro at P1’
resulted in fewer van der Waals contacts with PR than for other analogs with Phe, Nle or
Leu at P1’. The two complexes showed the largest deviation from PR/p2-NC for the
residues 48-52 in the flap region of both subunits. This structural change in the flaps and
the differences in interactions with the substrate side chains were consistent with the
poorer inhibition of PR by p6pol-PR compared to CA-p2 and p2-NC analogs.
PRV82A showed almost identical hydrogen bond and van der Waals interactions
with p6pol-PR compared to PR, except for interactions with the terminal P5Val and
P4’Thr. As noted previously, the N-terminus was very flexible and had two different
orientations when bound to PR or PRV82A. Thus, the N-terminal residues had van der
Waals interactions with totally different residues in the two complexes. In the case of
PRV82A, the N-terminus had lost the hydrogen bond at P5 position and, instead, had a
water-mediated interaction of P4 with Met 46. PR/p6pol-PR showed interactions of the Cterminus of p6pol-PR with Asp 60 and Gln 61 through a water molecule, while
PRV82A/p6pol-PR did not have those interactions. At the mutation site 82, however, most
interactions between protease and analog were conserved. Residue 82 interacted with P1
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and P1’ of p6pol-PR and small shifts were observed for both Ala 82 and P1Phe in
PRV82A/p6pol-PR compared to the positions in the PR complex (Figure 3.1.5C). These
structural changes resulted in good van der Waals interactions of Ala 82/82’ CB atoms
with P1’Pro/P1Phe and compensated for the loss of the methyl groups of Val 82 in PR.
The structural adjustment of the PRV82A mutant to accommodate inhibitor binding was
consistent with the similar inhibition constants observed for PRV82A and PR with p6pol-PR
(36 and 22 µM, respectively).

Structural comparison of the complexes with p1-p6 analog
The two complexes of PR/p1-p6 and PRV82A/p1-p6 were very similar with only
small changes in the interactions with p1-p6. The RMS deviation values on alpha carbon
atoms were 0.17-0.18 Å between these two complexes and PR/p2-NC. Analog p1-p6 was
bound to PR and PRV82A in two orientations with relative occupancy of 0.6/0.4. Residues
P5-P5’ of p1-p6 interacted with PR and PRV82A (Figure 3.1.4D). The N terminal P4 and
P3 of p1-p6 showed similar hydrogen bond and van der Waals interactions with protease
as in the p2-NC complexes, however, these differed from the interactions of p6pol-PR.
The long side chain of P4’ Arg at the C-terminus formed extra water-mediated
interactions with PR residues Trp 6, Arg 8, Asp 29’, Asp 30’ and Arg 87’. The major
difference from other substrate analogs was the presence of the small Gly at the P3
position in p1-p6. The P3 Gly had fewer van der Waals interactions with PR, and p1-p6
had more space to move around the binding pocket. As a result, although both p1-p6 and
p6pol-PR had Asn at P2, it showed different hydrogen bonds with PR. In p6pol-PR, the big
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C.

D.
Figure 3.1.5 Structural variation around residues 81 84 in p2-NC, p6pol-PR, p1-p6,
UIC-94017 and indinavir complexes.
The PR structure is in purple, PRI84V in green and PRV82A in blue bonds. Interatomic
distances (Å) are indicated by dashed lines.
C. PRV82A/p6pol-PR superimposed on PR/ p6pol-PR.
D. PRV82A/p1-p6 superimposed on PR/p1-p6.
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ring of P3Phe restricted movement in the binding site and pushed P2Asn more towards
the active site, which enabled P2Asn to form hydrogen bonds with Asp 29 and Asp 30.
While, with Gly at P3 the backbone of p1-p6 had moved in the binding site and provided
more flexibility for P2Asn. The side chain of P2Asn in p1-p6 adopted two conformations
differing by a rotation of about 90 degrees. One conformation of P2Asn maintained
weaker hydrogen bonds with Asp 29 and 30, while the other conformation was
surrounded by the hydrophobic side chains of Ile 50’, Ile 84, and P1’Leu. Also, there
were more water-intermediated interactions of PR with p1-p6. The loose binding of PR
and p1-p6 primarily due to P3Gly was consistent with its more than 50 times worse
inhibition than that of CA-p2 and p2-NC.
PRV82A showed similar movements of Ala 82 and p1-p6 compared to PR/p1-p6
(Figure 3.1.5D) as described for the complexes with p2-NC and p6pol-PR. Again, these
subtle structural changes allowed formation of improved van der Waals interactions
between PRV82A and P1’ and P1 of the substrate analog. The improved interactions with
substrate analog observed in PRV82A were compatible with its three times better inhibition
than PR, and with the higher relative kcat/Km for hydrolysis of the p1/p6 substrate (Feher
et al. 2002).

PR interactions with substrate analogs compared to those with clinical inhibitors
Substrate analogs showed more flexibility than clinical inhibitors in binding to the
mutant PRs. The high resolution crystal structures of PR, PRV82A and PRI84V complexes
indicated that the binding affinity for mutants was modulated by the conformational
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flexibility of P1 and P1’ side chains in the substrate analogs (Figure 3.1.5). It is
instructive to compare the PR and mutant complexes with the clinical inhibitors. The
crystal structures of PR, PRV82A and PRI84V with UIC-94017, an inhibitor in phase IIB
clinical trials, and PR, PRV82A and PRL90M with the drug indinavir, were determined at
resolutions of 1.1 – 1.6 Å (Mahalingam et al. 2004; Tie et al. 2004). All these structures
were superimposed on PR/UIC-94017 with RMS deviations on alpha carbon atoms of
0.15 to 0.25 Å. The clinical inhibitors maximize the interactions within PR subsites S2 to
S2’, while the longer substrate analogs have more extended interactions within S4 to S4’.
The UIC-94017 is smaller than the substrate analogs but formed similar hydrogen bonds
to PR main chain atoms. Compared to indinavir and other clinical inhibitors, UIC-94017
formed additional polar interactions with the main chain atoms of Asp 29 and Asp 30
(Mahalingam et al. 2004; Tie et al. 2004). These interactions resembled those of the P2’
Gln or Glu side chain of peptide analogs (Figures 3.1.1B and 3.1.5).
Similar rearrangements of residue 82/82’ and P1/P1’ were observed in PRV82A
complexes compared to PR complexes (Figure 3.1.5). These shifts allowed closer
contacts of Ala 82 and 82’ with the inhibitor, and partially compensated for the smaller
side chain of Ala compared to wild type Val. However, Ala 82/82’ showed smaller shifts
(0.1–0.4 Å of Cα) with substrate analogs and larger changes (0.5-0.8 Å) with clinical
inhibitors. These changes were coupled with larger movements or multiple conformations
of P1/P1’ side chains in substrate analogs (Figures 3.1.5A-D) than observed for the
inhibitors UIC-94017 or indinavir (Figures 3.1.5E and F). The flexible side chain of
P1’Nle in p2-NC adopted different conformations to maintain the interactions with
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E.

F.
Figure 3.1.5 Structural variation around residues 81 84 in p2-NC, p6pol-PR, p1-p6,
UIC-94017 and indinavir complexes.
The PR structure is in purple, PRI84V in green and PRV82A in blue bonds. Interatomic
distances (Å) are indicated by dashed lines.
E. PRV82A/UIC-94017 superimposed on PR/ UIC-94017.
F. PRV82A/indinavir superimposed on PR/indinavir.
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PRV82A. P1Phe in p6pol-PR and p1-p6 showed adjustments to interact better with Ala 82.
In contrast, Val 84 in PRI84V was less flexible than Ala 82 and adaptation in the
PRI84V/p2-NC complex was due to the alternate conformations of P1’Nle (Figure 3.1.5B).
Consequently, similar Ki values for PR and mutant PRV82A were observed for both
substrate analogs and UIC-94017 (0.3 to 1.6-fold) and increased by 3-fold for indinavir
(Wang et al. 1996), while the Ki increased from 2 to 6-fold for PRI84V (Tie et al. 2004).
Similar structural changes were reported for the inactive double mutant V82A/D25N
compared to D25N mutant in complexes with peptides or ritonavir (Prabu-Jeyabalan et
al. 2004). These observations suggested that the substrate analogs have more flexibility
to accommodate the structural changes caused by mutation of PR. Hence, the
comparison of PR complexes with substrate analogs or drugs helps to explain how the
virus can develop drug resistance while retaining the ability to catalyze the hydrolysis of
natural substrates.

Structure of active site and implications for reaction mechanism
These crystal structures of PR with reduced peptide analogs represent a transition
state in the reaction. Ideally, the reaction mechanism would be analyzed using a series of
crystal structures of active PR with peptide substrates and transition state analogs
representing different steps in the reaction. However, it is difficult to obtain crystal
structures of active PR with peptide substrates. Two strategies have been used to analyze
the structures of the transition state(s). We have analyzed structures of active PR with
reduced peptide analogs that mimic the transition state of the hydrolytic reaction since
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they contain an amine and tetrahedral carbon at the non-hydrolysable peptide bond.
Other groups have used an alternative strategy of crystallizing an inactive enzyme with
the D25N mutation in complex with peptide substrates (Prabu-Jeyabalan et al. 2002;
Prabu-Jeyabalan et al. 2003; Prabu-Jeyabalan et al. 2004). Comparison of the crystal
structures has helped to understand two different steps in the reaction. There were several
differences between our crystal structures of PR with peptide analogs and those of the
D25N inactive enzyme with peptides. The PR sequence differed in six amino acids, as
well as the D25/N25 difference. Also, most of the peptides had differences in sequence.
The two structures of D25N/p1-p6 (1KJF) and PR/p1-p6 that share similar peptide
sequences were compared. Overall, the RMS differences were 0.6 Å for main chain
atoms, as usually observed for PR crystal structures in different space groups. The most
striking difference was in the conformation of the peptide or reduced peptide backbone
atoms between P1 and P1’ (Figure 3.1.6A). These differences arise from the presence of
the planar peptide bond (CO-NH) in the peptide instead of the tetrahedral carbon in the
reduced peptide (CH2-NH). The tetrahedral carbon in the reduced peptide was much
closer to the Asp 25 and 25’ side chains than was the carbonyl carbon in the peptide bond
(the two carbon atoms were separated by 1.1 Å). The tetrahedral carbon atom of the
reduced peptide interacted with the four carboxylate oxygen atoms of Asp 25 and 25’ at
distances of 3.1-4.0 Å. In contrast, the peptide carbonyl oxygen of D25N/p1-p6 showed
one hydrogen bond interaction and one van der Waals interaction with the carboxylate
oxygens of Asp 25’. Furthermore, the tetrahedral carbon in the reduced peptide was in a
similar position to the tetrahedral carbon of CH-OH in the UIC-94017 inhibitor, which
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A.

B.
Figure 3.1.6 Structural variation around active site.
A. PR/p1-p6 is shown (colored by atom type) superimposed on D25N/p1-p6 (1KJF)
in green bonds. Distances within 4.0 Å are shown.
B. PR/UIC-94017 is shown in yellow bonds superimposed on PR/p1-p6 complex
(colored by atom).
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mimics the transition state and showed interactions of the hydroxyl group with all four
Asp 25/25’ carboxylate oxygen atoms (Figure 3.1.6B). Therefore, the PR complexes
with reduced peptide analogs more closely represented the tetrahedral transition state of
the reaction, while the D25N/peptide structures are likely to represent the initial step of
substrate binding to the PR.

Special feature in electron density map around the active site
The atomic resolution structure of PRV82A/p2-NC showed unusual Fo-Fc
difference density at the catalytic site that may relate to the reaction mechanism. The
other crystal structures showed little or no difference density around the catalytic site. In
these substrate analogs, the carbonyl group of P1 has been reduced to a methylene group
to prevent hydrolysis. However, significant Fo – Fc positive difference density was
observed close (about 1.4 Å) to the reduced carbon atom on P1Nle (norleucine) (Figure
3.1.7). Previous crystallographic studies of HIV-1 PR in complex with a pseudo-C2
symmetric inhibitor and molecular dynamic calculations suggested that the
difluoroketone core was hydrated and that the hydration of the carbonyl group is the
initial step for HIV-1 PR catalysis (Slee et al. 1995; Silva et al. 1996). Therefore, a
hydroxyl was tested in the positive density. No reduction in the difference density was
observed in tests with various other atoms (H, Na or O). The positive difference density
was decreased, but not eliminated, only when a hydroxyl group was added to the reduced
carbon atom. The refinement used a standard Nle and hydroxyl-Nle with relative
occupancy of 0.7/0.3. Mass spectroscopic studies of crystals and separated peptide analog
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Figure 3.1.7 Electron density maps at the active site of PRV82A/p2-NC complex.
The 2Fo−Fc map is green and was contoured at a level of 2.2 , whereas the Fo−Fc map
is contoured at 3.2 and colored purple for positive.
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did not show any significant change in molecular mass of either PR or inhibitor.
Therefore, any modification of the p2-NC analog must be transient at best and occurred
only in the crystal structure. Moreover, hydration of the reduced carbon is an
energetically unfavorable event. Thus, it is not clear whether the hydroxyl-Nle exists.
Further analysis of the data by charge density analysis or quantum calculations will be
necessary to understand the observed difference density at the active site, and may help to
understand the catalytic mechanism.
These high resolution crystal structures of HIV PR with natural cleavage substrate
analogs provide new molecular details to understand the specificity of substrate
recognition and a basic framework for the design of new inhibitors that are more effective
against resistant HIV. The results have been published in (Tie et al. 2005).
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3.2 Structural analysis of protease complexes with UIC-94017 (TMC-114)
Specific aim: To determine & analysis crystal structures of PR and mutants PRV82A,
PRI84V, PRD30N and PRI50V with UIC-94017
Comparison of these atomic resolution crystal structures will help to understand
the effects of mutation in protease and evaluate the structural modification of proteaseinhibitor complexes. Crystal structures of wild-type PR, PRV82A, PRI84V, PRD30N and
PRI50V in complex with UIC-94017 have been determined at 1.10-1.53 Å resolution and
similar hydrogen bonding interactions are shown between protease and inhibitor. The
hydrogen bonds between UIC-94017 with the main chain atoms of Asp 29 and 30 in the
protease are demonstrated, which is critical for the potency and activity of this compound
against multiple PI-resistant HIV.

Chemical synthesis of UIC-94017
The synthesis of UIC-94017 (1) was done by Dr. Arun Ghosh’s lab and is
outlined in Figure 3.2.1. Commercially available optically active epoxide 3 (Ghosh et al.
1998a) was reacted with isobutylamine in 2-propanol at 84°C for 6 h. The resulting
amino alcohol was reacted with 4-nitrobenzenesulfonyl chloride to provide the
sulfonamide derivative 3 (Ghosh et al. 1998b). Reduction of nitro group of 4 by catalytic
hydrogenation over 10% Pd-C in ethyl acetate provided the corresponding aromatic
amine. Trifluoroacetic acid promoted removal of BOC-group followed by reaction of the
resulting diamine with mixed carbonate 5 (Ghosh et al. 1995) furnished inhibitor 1
(Ghosh et al. 1996) selectively. Synthesis of UIC-94017 was confirmed by 1H-NMR.
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Figure 3.2.1 Synthesis of UIC-94017.
Reagents and conditions: (a) Me2CHCH2NH2, 2-propanol, 84°C, 6 h; (b) p-NO2C6H4SO2Cl, aq. NaHCO3, CH2Cl2; (c) H2, 10% Pd-C, EtOAc; (d) CF3CO2H, CH2Cl2;
(e) 5, Et3N then diamine.
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Enzyme kinetics and relative inhibition of PRV82A, PRI84V, PRD30N and PRI50V
PR and the set of drug-resistant mutant proteases (PRV82A, PRI84V, PRD30N, PRI50V,
and PRL90M) catalyze the hydrolysis of the fluorescence substrate, an analog of the MACA cleavage site in the Gag-Pol polyprotein, and their catalytic activities are
competitively inhibited by UIC-94017. Saturation kinetics were observed for PR,
PRV82A, PRI84V, PRD30N, PRI50V and PRL90M - catalyzed hydrolysis of substrate. The
kinetic parameters are summarized in Table 3.2.1. Mutants varied in their catalytic
activity for the fluorescence substrate compared to PR. Except for the dramatically lower
kcat for PRD30N (0.2 min-1) and >2 times higher kcat for PRL90M (7.6 min-1), the kcat value
for the others was in the range of 1.7-2.7 min-1. The Km value had less change (26-57
µM). Overall, similar kcat/Km values were observed for PR, PRV82A and PRI84V, while
PRD30N and PRI50V showed only 0.09 and 0.38 fold of the PR value, respectively, and that
of PRL90M was 2.6 fold of PR value. PRV82A and PRI84V showed little increase in Ki for
UIC-94017, with value of 3.6 and 5 fold in relative to that of PR, respectively. PRI50V and
PRD30N had larger change of 9 and 30 fold compared to the Ki of PR. Surprisingly,
PRL90M showed only 0.14 fold of the Ki value for PR, which suggested that it was 7 times
better inhibited by UIC-94017 than PR. The order of relative inhibition for UIC-94017
was PRL90M >> PR > PRV82A > PRI84V > PRI50V > PRD30N. A slightly different order of
inhibition was shown for indinavir (IDV), which was PR ≈ PRL90M > PRV82A > PRI84V >
PRD30N > PRI50V. Mutants PRV82A and PRI84V had similar Ki relative to PR value for UIC94017 and indinavir. Most of the other clinical inhibitors showed significantly poorer
relative inhibition of the protease with V82A or I84V mutations, except for amprenavir,

Table 3.2.1 Kinetic data.
Kinetic parameters for protease-catalyzed hydrolysis of fluorescence substrate [Ac-RE(Edans)SQNY*PIVRK(Dabcyl)R-CONH2, where * indicates the cleavage site], and inhibition constants for the hydrolytic reaction with the inhibitor UIC-94017 (or
IDV)
KM
(µM)

kcat
(min-1)

kcat/KM
(mM-1min-1)

Ki (UIC-94017)
(nM)

relative Ki
(UIC-94017)

Ki (IDV)
(nM)

relative Ki
(IDV)

PR

36 ± 8

2.7 ± 0.5

77 ± 20

0.22 ± 0.05

1

0.6 ± 0.1

1

PRV82A

26 ± 2

2.4 ± 0.1

90 ± 8

0.8 ± 0.06

3.6

1.3 ± 0.1

2.2

PRI84V

39 ± 7

2.0 ± 0.2

50 ± 10

1.1 ± 0.2

5

2.5 ± 0.3

4.2

PRI50V

57 ± 11

1.7 ± 0.2

29 ± 7

2.0 ± 0.4

9

10.4 ± 1.0

17

PRD30N

31 ± 5

0.21 ± 0.02

7±1

6.6 ± 1.0

30

7.0 ± 1.0

12

PRL90M

38 ± 5

7.6 ± 0.7

200 ± 34

0.03 ± 0.004

0.14

0.8 ± 1.0

1.3
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which had only 2- and 3-fold increased Ki for PRV82A and PRI84V mutants, respectively
(Gulnik et al. 1995; Klabe et al. 1998). UIC-94017 was 3 fold worse than indinavir for
the inhibition of PRD30N, a mutant most commonly found on exposure to nelfinavir.
However, UIC-94017 had 2 to 10 fold lower relative Ki (better inhibition) than indinavir
for PRI50V and PRL90M. This is consistent with the potency of UIC-94017 against HIV-1
drug- resistance strains (Koh et al. 2003). Furthermore, UIC-94017 is more effective on
PRI50V than is indinavir, even though PRI50V commonly occurs with the treatment of
amprenavir, which is chemically most similar to UIC-94017.

Description of the high resolution crystal structures
The crystal structures of PR and drug resistant mutants (PRV82A, PRD30N, PRI50V
and PRI84V) have been determined in complexes with UIC-94017. Crystallographic
statistics are summarized in Table 3.2.2. The crystallographic asymmetric units contain a
PR dimer with the residues in the two subunits numbered 1-99 and 1’-99’. The three
structures were determined in two different space groups (P21212 and P212121) and were
refined to resolutions of 1.10-1.53 Å and R-factors of 0.12-0.15 including solvent
molecules, anisotropic B-factors and hydrogen atoms. These high resolution crystal
structures showed excellent electron density for all the protease atoms, the inhibitor, and
solvent molecules. The electron density map for Tyr 59’ and interacting atoms in the PR
structure is shown in Figure 3.2.2. The average B-factors were low for protein and
inhibitor atoms. The highest resolution structure of PRV82A had the lowest R-factor.
PRV82A showed the lowest average B-factors of 8.0 Å2 for protein main chain atoms

Table 3.2.2 Crystallographic data statistics.
PR
P21212
58.26
85.91
46.05
50-1.30
56890
6.5
(26.8)
10-1.30
13.42
17.34
210
98.6
(90.2)

PRV82A
P212121
50.79
57.87
61.94
50-1.10
74707
5.2
(19.6)
10-1.10
11.74
14.53
221.6
99.7
(97.6)

Space group
Unit cell
a
dimensions
b
(Å)
c
Resolution range (Å)
Unique reflections
Rmerge (%)
Overall (final shell)
Data range for refinement (Å)
Rwork (%)
Rfree (%)
No. of solvent (total occupancies)
Completeness (%)
Overall (final shell)
RMS deviation from ideality
0.014
0.016
Bonds (Å)
0.038
0.037
Angle distance (Å)
2
Average B-factors (Å )
14.9
8.0
Main chain
19.2
13.1
Side chain
10.8
7.4
Inhibitor
31.1
24.1
Solvent
0.6/0.4
1*
Relative occupancies of alternate
conformations of UIC-94017
*Only the aniline ring had two orientations with occupancy distribution of 0.6/0.4.

PRI84V
P21212
50.79
57.87
61.94
50-1.53
35966
8.2
(31.2)
10-1.53
12.98
19.65
193
99.3
(97.3)

PRD30N
P212121
58.49
86.13
45.94
50-1.45
40644
8.9
(57.5)
10-1.45
15.2
21.8
178.0
98.0
(86.0)

PRI50V
P21212
58.70
85.79
46.15
50-1.22
64113
9.0
(40.2)
10-1.22
13.0
18.8
171.1
91.9
(53.3)

0.012
0.035

0.011
0.034

0.014
0.037

15.9
21.9
14.1
32.1
0.7/0.3

16.2
22.7
12.9
33.4
0.5/0.5

15.4
19.9
12.9
28.8
0.6/0.4
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compared to values of about 15 Å2 for the other structures. The inhibitor atoms also had
the lowest average B-factors for the complex with PRV82A: 7.4 Å2 compared to 10.8, 14.1,
12.9 and 12.9 Å2 for PR, PRI84V, PRD30N and PRI50V, respectively.
Alternate conformations were modeled for residues in all the crystal structures.
There were 36 residues with two alternate conformations modeled for PR, 37 for PRV82A,
41 for PRI84V mutant, 18 for PRD30N mutant and 35 for PRI50V mutant (Table 3.2.3).
There was clear electron density for the alternate positions of these side chains, as shown
by the examples in Figure 3.2.3. The residues with alternate conformations were not the
same in both subunits, or in all five structures. However, four of the structures, PR,
PRI84V, PRD30N and PRI50V showed a similar pattern, probably because they were in the
same space group P21212 and both showed two conformations of the inhibitor. Most
alternate conformations were observed for the side chains of surface residues, especially
residues with longer side chains, such as arginine, lysine, glutamine and glutamic acid.
The side chains of Ile 33’, Ile 64, Leu 89, and Leu 97 are in internal hydrophobic regions.
The side chains of seven amino acids which interact directly with the inhibitor, Arg 8,
Asp 30, Val 32, Ile 47, Ile 50, Pro 81, Val 82, and Ile 84, showed alternate conformations
in at least one subunit. Disorder was previously reported for Val 32, Val 82 and Ile 84 in
ternary complexes of protease bound to substrate analogs (Mahalingam et al. 2001).
The main chain atoms of Ile 50 and 50’ in the two subunits had two alternative
conformations, with relative occupancies of 0.6 to 0.4, in the four structures with space
group P21212. The carbonyl groups in these two residues can flip about 180 degree and
still form the hydrogen bonds between the carbonyl oxygen atom and amide nitrogen
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Table 3.2.3 Residues with alternate conformations.
The side chains have alternate conformations in most cases.
*main chain atoms have alternate positions. #alternate positions for both main chain and
side chain atoms. A, B indicate the subunit. Residues in inhibitor binding site are
indicated in bold.
Residue
Thr 4
Leu 5
Trp 6
Lys 7
Arg 8
Lys 14
Gln 18
Lys 20
Glu 21
Asp/Asn 30
Val 32
Ile 33
Glu 34
Glu 35
Met 36
Ser 37
Leu 38
Pro 39
Gly 40
Arg 41
Trp 42
Lys 43
Lys 45
Met 46
Ile 47
Ile/Val 50
Gly 51
Lys 55
Arg 57
Gln 61
Ile 63
Ile 64
Glu 65
Lys 70
Pro 81
Val/Ala 82
Ile/Val 84
Leu 89
Leu 97

PR

AB
AB
AB
B
AB
AB
B
B

AB

A
B
B
AB

PRV82A
A#
A*
B
A
AB
AB
A
AB
B
A
B
B
B
A
AB
B
B*
AB
AB
AB
B

A*B#
A*B*
A

AB
AB
B
AB
AB
AB

PRI84V

PRD30N

PRI50V

AB
AB
AB
B

AB

AB
AB
AB
B

AB
AB
B
B
AB
B
A

A
B
AB
AB
AB
A*B#

B
AB
B#

AB
B#
B

A

A

AB

AB

A

B
A*B*
A*B*

A*B#
A*B*
A
A

A

B

B
AB
B
AB
AB

AB

AB

AB
B
A
A
A#
AB
B
A
A

B
B
AB

AB
AB
AB
AB
B
A
AB
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3.0

VAL 75’

TYR 59’

2.9

ARG 57’

2.6

Figure 3.2.2 2Fo-Fc electron density map for Tyr 59’ of PR complex.
The contour level is 1.7 σ. Hydrogen bonds are indicated by dashed lines with the
interatomic distance in Å.

ILE 47’

MET 46
A.

B.

Figure 3.2.3 Alternate side chain positions of residues in PRV82A structure shown in
2Fo-Fc map.
The 2Fo-Fc map was contoured at a level of 1.7 σ. The major conformation is colored by
atom type, and the minor conformation is in green.
A) Met 46.
B) Ile 47’
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atom of each residue that link the tips of the flaps. The structure of PRV82A in space
group P212121 showed two alternative conformations of the main chain atoms between
residues 4 and 5, which are located at the dimer surface. Ile 64 in PRV82A had alternate
main chain and side chain conformations in an internal hydrophobic region. The
occupancy distribution was 0.7 to 0.3 and the two conformations interacted with the same
surrounding residues.

Solvent structure in the crystals
Previous crystal structures of HIV protease-inhibitor complexes were modeled
with a single shell of solvent molecules (Mahalingam et al. 1999; Mahalingam et al.
2001). The high quality of diffraction data for the structures described here permitted the
modeling of a second shell of solvent (Figure 3.2.4B). The solvent was modeled with
more than 200 water molecules, ions and other small molecules from the crystallization
solutions, including many with partial occupancy, depending on the shape of the electron
density and the interactions with other molecules. The ions modeled were sodium,
chloride, acetate, sulfate and phosphate. Glycerol and DMSO were fitted to density in the
PR, PRV82A, PRD30N and PRI50V. Examples of the electron density maps for solvent
regions are shown in Figure 3.2.4. The average B-factors for the solvent atoms were 24.1
Å2 for PRV82A and 29-33 Å2 for PR, PRI84V, PRD30N and PRI50V complexes.
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A.

B.
Figure 3.2.4 2Fo-Fc electron density maps for solvent molecules.
The 2Fo-Fc map was contoured at a level of 1.7 σ. Hydrogen bonds are indicated by
dashed lines with the interatomic distance in Å.
A) Phosphate ion in PRV82A complex.
B) A set of interacting water molecules in PRV82A complex.
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C.

D.
Figure 3.2.4 2Fo-Fc electron density maps for solvent molecules.
The 2Fo-Fc map was contoured at a level of 1.7 σ. Hydrogen bonds are indicated by
dashed lines with the interatomic distance in Å.
C) Sodium ion in PRI50V complex.
D) Glycerol molecule in PR complex.
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Protease-inhibitor interactions in PR/UIC-94017 complex
The crystal structure of HIV-1 PR showed two pseudosymmetric positions of
UIC-94017 with relative occupancy of 0.55/0.45 (Figure 3.2.5A). The side chains of
several amino acids in the binding site showed two conformations, as observed
previously for hydrophobic side chains near the peptide analogs (Mahalingam et al.
2001). The inhibitor P1 and P1’ groups form van der Waals interactions with protease
residues Leu 23, Gly 49, Ile 50, Pro 81, Val 82, and Ile 84 from both subunits. The end
groups interact with residues Ala 28, Asp 29, Asp 30, Val 32, Ile 47 and Ile 50. The CG
atom of Pro 81’ in the PR structure interacts closely with the inhibitor and shows
alternate positions with the occupancy distribution of 0.55 to 0.45, which is the same as
that of the inhibitor. This suggests that the alternate conformations of the amino acid side
chains correlate with those of the inhibitor. Theoretically, the greater flexibility of the
structure will increase the entropy and in turn reduce the interaction energy between
protein and inhibitor. The PR-inhibitor hydrogen bond interactions are shown in Figure
3.2.6A. Equivalent interactions exist for both positions of the inhibitor (Table 3.2.4). The
inhibitor hydroxyl group interacted with all four carboxylate oxygens of the catalytic Asp
25 and 25’, which mimics the interactions of its tetrahedral transition state of the
protease. The carbonyl oxygen and one of the sulfonamide oxygen atoms form hydrogen
bonds with the water that interacts with the amides of Ile 50 and 50’ on the flaps, as
observed in most HIV protease-inhibitor complexes (Gustchina et al. 1994). This water
is conserved in all structures of PR with inhibitors/substrates except for those urea-based
inhibitors designed explicitly to substitute this H2O, such as DMP323 and DMP450
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A.

B.
Figure 3.2.5 Electron density map of UIC-94017.
The omit map was contoured at a level of 3.2 σ.
A. Electron density map of UIC-94017 in PR complex. UIC-94017 is shown in two
pseudosymmetric overlapping positions in red and blue bonds.
B. Electron density map of UIC-94017 in PRV82A complex.
The map shows one position of UIC-94017 with two conformations for the aniline group.

Table 3.2.4 Protease-inhibitor hydrogen bond interactions.
The protease-UIC-94017 interatomic distances are shown for the crystal structures of PR, PRV82A, PRI84V, PRD30N and PRI50V
complexes. Except for PRV82A, other complexes have two positions of UIC-94017. The atoms of the major UIC-94017
conformation and interacting PR atoms are indicated in bold. The Asp 25 and 25’ carboxylate oxygen atoms interacted with
OH in both positions of UIC-94017. PRV82A had one UIC-94017 with two conformations for the aniline group that had
different interactions. *The minor conformation of the aniline NH2 interacted with Asp 30 OD2. mThe major conformation of
30/30’and # the minor conformation of 30/30’. Two water molecules are indicated as H2OA and H2OB. Distances of more
than 3.4 Å are in parentheses to indicate they are too long for good hydrogen bond interactions.
The interatomic distances are shown for equivalent atoms of amprenavir from 1HPV crystal structure.
Protease
UIC-94017
Distance (Å)
atom
Atom
PR
PRV82A
PRI84V
PRD30N
PRI50V
WT-AMP
Asp 25 OD1
OH
2.7/2.8
3.0
2.6/2.9
2.7/2.6
2.6/2.7
2.6
Asp 25 OD2
OH
2.6/3.1
2.5
2.4/3.1
2.5/2.8
2.5/3.1
3.1
Asp 25’ OD1
OH
2.8/2.6
2.5
2.7/2.5
2.7/2.5
3.0/2.7
2.7
Asp 25’ OD2
OH
3.2/2.6
3.2
3.1/2.5
3.0/2.7
3.3/2.6
2.8
Gly 27’/27 O
NH
3.2/3.2
3.1
3.1/3.2
3.2/3.2
3.2/3.1
(3.6)
Asp 29’/29 NH
O26
3.1/3.0
3.0
3.1/3.1
3.1/3.1
3.1/3.1
(3.5)
Asp 29’/29 OD2
O28
3.2/3.2
3.3
3.2/3.1
3.3/3.3
3.1/3.3
Asp 29’/29 NH
O28
3.0/2.9
2.9
2.9/3.0
2.9/2.9
3.0/2.9
Asp (Asn) 30/30’ O
NH2
3.3/3.2
(3.5)
3.2/3.4
3.2/3.0#
(4.1)/3.2#2.9m
(3.6)
Asp (Asn) 30/30’
NH2
2.7/2.8
2.8/2.9*
2.4/2.6
2.5/2.8
3.1
OD2(ND2)
Asp (Asn) 30/30’ NH
NH2
3.2/3.0
(3.5)*
3.2/3.1
3.2/3.0
3.4/3.0
3.2
Asp (Asn) 30’/30 NH
O26
3.3/3.3
3.1
3.3/(3.5)
3.3/3.0
3.4/3.3
(3.5)
H2OA
O22
3.0/3.0
2.8
2.9/3.1
2.9/3.1
3.1/2.9
3.0
H2OA
O10=S
2.4/2.4
2.8
2.4/2.3
2.5/2.4
2.3/2.6
2.8
H2OA
O9=S
3.3/3.2
(3.5)/3.2
3.4/3.4
3.4/(3.5)
3.4
Ile (Val) 50 N
H2OA
2.9
3.0
2.9
3.0
3.0
2.7
Ile (Val) 50’ N
H2OA
2.9
2.9
3.0
2.9
2.9
2.9
H2OB
NH2
2.4
3.2/2.9
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(Lam et al. 1994; Hodge et al. 1996; Lam et al. 1996). No other water-mediated
interactions were observed between PR and UIC-94017. The two oxygen atoms of the
bis-THF group of the inhibitor are positioned to form hydrogen bond interactions with
the main chain amides of Asp 29 and Asp 30. The bis-THF O28 also formed a close
interaction with the OD2 of Asp 29, similar to the proton-mediated interaction observed
between Asp 29 and peptide analogs with P2’ Glu (Mahalingam et al. 2001). The amino
group at the other end of the inhibitor interacts with the main chain carbonyl oxygen and
the side chain carboxylate oxygen of Asp 30’.

Comparison of the structures of PR/UIC-94017 and PR/amprenavir
It is instructive to compare the protease interactions of UIC-94017 with those of
the structurally related inhibitor, amprenavir. The crystal structure of wild type protease
with amprenavir was determined at 1.9 Å resolution (Kim et al. 1995) (PDB: 1HPV).
Amprenavir had fewer hydrogen bond interactions with the protease than observed for
UIC-94017 (Table 3.2.4; Figure 3.2.6B). The detailed comparison for two distal ends of
two inhibitors is shown in Figure 3.2.7. The single THF ring on amprenavir was more
than 3.5 Å away from the protease and no hydrogen bond was formed, while the
modified bis-THF ring on UIC-94017 had tight hydrogen bonds with the main-chain
atoms of residues Asp 29’ and Asp 30’. The difference in the size of the THF ring further
induced slight change in the shape of the inhibitor, so even though amprenavir has the
same aniline end as UIC-94017, the NH2 group of amprenavir formed a weaker hydrogen
bond interaction with the carboxylate oxygen of Asp30 (3.1 Å compared to 2.7 Å in

A.
Figure 3.2.6A Hydrogen bond interactions of PR with UIC-94017 (1S6G).
The PR residues forming hydrogen bond interactions with the major position of UIC-94017 are shown. The interactions of the
minor position of UIC-94017 are essentially identical (Table 3.2.4). The red sphere indicates a water molecule. Hydrogen
bonds are indicated by dashed lines with red lines representing the interactions between the inhibitor to the main chain atoms
of PR.
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B.

C.
Figure 3.2.6B Hydrogen bond interactions of PR with amprenavir (1HPV).
The PR residues forming hydrogen bond interactions with amprenavir are shown.
Hydrogen bonds are indicated by dashed lines with red lines representing the interactions
between inhibitor to the main chain atoms of PR.
Figure 3.2.6C Hydrogen bond interactions of PR with indinavir (1SDT).
The PR residues forming hydrogen bond interactions with the major position of indinavir
are shown. The interactions of the minor position of indinavir are essentially identical.
The red sphere indicates a water molecule. Hydrogen bonds are indicated by dashed lines
with red lines representing the interactions between inhibitor to the main chain atoms of
PR.
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A.

B.
Figure 3.2.7 Major differences in PR interactions with UIC-94017 and amprenavir.
The hydrogen bond interactions of PR residues Asp 30, Asp 29’ and Asp 30’ with UIC94017 and amprenavir are compared in a stereo view. Hydrogen bond interactions are
indicated by dashed lines. The atoms and interactions in the PR/UIC-94017 structure are
green, and the PR/amprenavir atoms and interactions are in red.
A. Overall difference
B. Detail difference at bis-THF ring
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PR/UIC-94017 complex) and lost the one with the main-chain oxygen atom of Asp30, as
seen in PR/UIC-94017 complex. Amprenavir and UIC-94017 have similar hydrophobic
groups with the exception of the bis-THF at one end of UIC-94017. Therefore, many of
the hydrophobic interactions with PR are similar for both inhibitors. The bis-THF group
of UIC-94017 introduced one very short van der Waals contact of 2.9-3.0 Å with the
main chain carbonyl oxygen of Gly 48, which cannot occur in amprenavir. However,
both UIC-94017 and amprenavir showed little change in Ki values for PR and mutants
PRV82A and PRI84V (Table 3.2.1) (Klabe et al. 1998). And surprisingly, an improvement of
9 times lower relative Ki to wild-type PR was obtained for PRI50V with UIC-94017
(relative Ki of 9) compared to that of amprenavir (relative Ki of 83) (Pazhanisamy et al.
1996), although different assay conditions may have been used.

Comparison of protease interactions in UIC-94017 and indinavir complexes
Since crystal structures with another clinical drug indinavir (IDV) have been
obtained for the wild-type PR and mutant proteases PRI50V, PRV82A and PRL90M in our lab
(Mahalingam et al. 2004; Liu et al. 2005) and a complete set of kinetic data had been
measured (Table 3.2.1), it will be useful to compare the protease interactions of UIC94017 with those of indinavir. The PRI50V/IDV complex had the highest resolution of
1.10Å, while the others were of resolution of 1.25-1.40 Å, which are comparable to the
values for the protease/UIC-94017 crystals. The indinavir structures showed mostly one
orientation of the inhibitor, except for PRI50V/IDV, which had two orientations of IDV
similar to the complexes with UIC-94017. Low RMS deviation values (less than 0.3 Å)
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were calculated for the structures in the same space group, while higher values of about
0.6 Å were obtained for those complexes in different space groups. The same trend has
been observed for all other protease-inhibitor/substrate structures.
Hydrogen bonds are the strongest interactions that play a major role in stabilizing
inhibitor/substrate binding in the protease cleavage site. To minimize the effect caused
by mutation at side-chain, UIC-94017 inhibitor was designed to increase the number of
strong favorable interactions with the protease, especially with the main-chain atoms.
Both indinavir and UIC-94017 have the hydroxyethyl isostere as the center of the
molecule, which mimics the transition state of the natural substrate during proteolysis
reaction. This hydroxyl group forms strong hydrogen bonds with all four carboxylate
oxygens of catalytic Asp25 and Asp25’. Other than these four hydrogen bonds, in the
protease/IDV complex, only three direct interactions were made between one end of the
inhibitor and protease residues Gly27, Asp29 and Asp30, two of which were with the
main chain atoms (Figure 3.2.6C). In PRI50V/IDV and PRL90M/IDV complexes, additional
hydrogen bonds were observed between IDV and the side chain of Arg8. Three water
molecules (besides the one between flap and inhibitor) mediated extra interactions
between PR and indinavir. Compared to IDV, in protease/UIC-94017 structures, the bisTHF group formed three extra direct hydrogen bonds to the main-chain NH groups of
Asp29 and Asp/Asn30 and lost the one with the side chain of Asp/Asn30; and the
presence of NH2 group at the other end of the inhibitor allowed for three additional direct
hydrogen interactions to Asp29’ and Asp/Asn30’ (Figure 3.2.6A). Except for the one
H2O between flap and inhibitor, no other water-mediated interaction between protease
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and inhibitor was observed in PR/UIC-94017 complexes. However, direct hydrogen
bonding is more favorable and conserved than water-mediated interactions. As expected,
the water-mediated hydrogen bonds were not conserved in all mutant/IDV structures. So
apparently, the inhibitor-main chain contacts are more conserved and less susceptible to
mutations than the interactions with the side chains or intermediated by water. The
significant difference in the hydrogen bond network of UIC-94017 and indinavir,
especially the capability of making more hydrogen bonds to the main-chain atoms of
protease by UIC-94017 provides the basis of the superiority of new inhibitor UIC-94017
over other known inhibitors.
Hydrophobic interactions are another important component for an inhibitor
binding. Yet, the relationship between the amount of hydrophobic contacts within the
protease and an inhibitor and the inhibitor’s ability to suppress the activity of the protease
mutants is not clear. A similar number of protease-inhibitor hydrophobic interactions
was found in PRV82A/IDV and PR/IDV complexes, while the Ki value of mutant V82A
increased to two fold of that of PR. In contrast, the Ki value for UIC-94017 was three
times higher for PRV82A than for PR, while about 12 interactions were lost in
PRV82A/UIC-94017 structure compared to PR/UIC-94017.

Comparison of inhibitor interactions in PR and mutants
Four protease/inhibitor structures in the current series were obtained in same
space group, P21212, while the PRV82A was the only one crystallized with UIC-94017 in
the space group P212121. The mutant structures in the same space group were very
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similar, with the RMS deviations from PR of around 0.1 Å for the Cα atoms. The PRV82A
complex had a larger RMS deviation of 0.35 Å compared to PR, due to the differences in
lattice packing in the two space groups. Big deviations of more than 1 Å were observed
for regions of residues 37-40, 37’-48’ and 54’-56’, which were mostly located on the
surface of the protein. The catalytic residues 25-27 showed very low RMS deviations of
0.02-0.12 Å for comparison of main chain atoms, consistent with the uniquely conserved
active site. UIC-94017 had very similar conformation and interactions in all five
structures, with the exception of the aniline group, which had two conformations in the
PRV82A structure. The occupancy distributions of two conformations of inhibitor are listed
in Table 3.2.2. The hydrogen bond network and hydrophobic interactions were
comparable for PR and all four mutants with some small variations caused by the point
mutations.
PRV82A/UIC-94017 showed ordered density for the inhibitor and two
conformations for the aniline group as shown in Figure 3.2.5B. The hydrogen bond
interactions with UIC-94017 were very similar to those of wild type enzyme except for
those of the amino group (Table 3.2.4). The two conformations of the aniline group had
relative occupancy of 0.56/0.44. Both conformations of the NH2 group formed hydrogen
bond interactions with the carboxyl oxygen of Asp30, as observed for PR. One
conformation also had a weak (3.5 Å) hydrogen bond with the carbonyl oxygen of
Asp30, similar to that observed for wild type enzyme. However, the NH2 group in the
other conformation interacted with a water molecule instead. These small differences
suggested that PRV82A had weaker polar interactions with UIC-94017 compared to those
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of PR. Almost identical numbers of van der Waals interactions between protease and
inhibitor were observed in PR and PRV82A (91 contacts of less than 4.0 Å for PRV82A
compared to 91 for PR). However, PRV82A showed a shift in the position of the main
chain atoms compared to those observed for PR (Figure 3.2.8). The shift of 0.5 Å on the
α-carbon atom of residue 82, together with the small shift of the benzene ring of UIC94017, placed the β-carbon atom of Ala82 at 3.8-4.0 Å from the closest inhibitor atom,
compared to 4.1 Å for β-carbon atom and 3.5-3.6 Å for γ-carbon atom of Val82 (Figure
3.2.8A). The other subunit showed a larger shift of 0.8 Å of Ala82 Cα that positioned the
β-carbon atom of Ala82’ at 4.1 Å from inhibitor, compared to 3.9 Å for Val82’ (Figure
3.2.8B). These small shifts result in good van der Waals interactions of β-carbon atom of
Ala82 with inhibitor and partially offset the loss of the methyl groups of Val 82. The
structural adaptation of the PRV82A mutant to accommodate the UIC-94017 inhibitor is
consistent with the similar inhibition values observed for PRV82A (relative Ki of 3.6) and
PR.
The PRI84V-inhibitor hydrogen bond interactions were essentially identical to
those of PR, except that the lower occupancy conformation of inhibitor showed a weak
(3.5 Å) interaction with the amide of Asp 30 (Table 3.2.4). The PR and PRI84V had almost
same hydrophobic contacts with inhibitor. There were 93 and 90 contacts of less than 4.0
Å calculated for the major conformation of UIC-94017 in PR and PRI84V, respectively.
PRI84V mutant showed very similar main chain structure around the mutated residue
compared to the wild type structure, as shown in Figure 3.2.9. Residue Ile84 in PR had
two conformations of its side chain and both showed good van der Waals interactions
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A.

B.
Figure 3.2.8 Interactions of mutated residue with UIC-94017 shown in
superimposed PRV82A and PR structures.
Only the P1 and P1’ groups of UIC-94017 are shown with the interacting protease
residues. Interatomic distances are indicated by dashed lines with the separation in Å.
PRV82A is shown in blue bonds and PR in purple. The major conformation is shown for
the side chains of Val 82 and 82’ in PR for clarity, whereas the minor orientation had the
similar interactions compared to major one.
A) PR compared to PRV82A near residue 82.
B) PR compared to PRV82A near residue 82’.
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A.

B.
Figure 3.2.9 Interactions of mutated residue with UIC-94017 shown in
superimposed PRI84V and PR structures.
Only the P1 and P1’ groups of UIC-94017 are shown with the interacting protease
residues. Interatomic distances are indicated by dashed lines with the separation in Å.
PRI84V is shown in green bonds and PR in purple. The two alternate conformations with
similar occupancy are shown for the Ile84 side chain in PR.
A) PR compared to PRI84V near residue 84.
B) PR compared to PRI84V near residue 84’.
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with the inhibitor with interatomic distances of 3.8 to 4.1 Å (Figure 3.2.9A), whilst
Ile84’in other subunit had only one position of its side chain and was at least 4.3 Å away
from the inhibitor (Figure 3.2.9B). These close van der Waals interactions with inhibitor
of Ile84 were lost in PRI84V, consistent with the observed 5-fold lower inhibition of
PRI84V compared to PR.
As mentioned above, the two ends of the UIC-94017 are the good hydrogen-bond
donor (aniline group) and acceptor (bis-THF group). Due to the presence of two inhibitor
conformations these groups occupied almost the same sites and formed a tight hydrogen
bond network with both Asp29/30, and Asp29’/30’. The p-NH2 substituent of the aniline
moiety interacted closely with residue 30 or 30’, including contacts with both the mainchain atoms: amide nitrogen and carbonyl oxygen, and the side-chain carboxyl group.
These hydrogen bonds were similar in the wild type and the mutant structures with
differences observed in PRD30N and PRI50V complexes. In PR structure, Asp30 had
alternate conformations with occupancies of about 50/50 % in both subunit, probably
related to the two conformations of inhibitor, and same direct hydrogen bonds were
established, as shown in Figure 3.2.10A. However, in PRD30N structure, clear electron
density suggested a single position for Asn30 (Figure 3.2.10B) and two possible positions
for Asn30’ (Figure 3.2.10C), and both of them had a water linking the side-chain
carboxylate of residue 30 to the p-amino of inhibitor instead of the direct contact
observed in PR, while the interactions of the main-chain atoms of Asn30/30’ were
maintained. Such water-mediated interactions with both residues 30 and 30’ were not
present in any other structure. Yet, in the PRD30N structure, the bis-THF oxygens had
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A.

B.

C.
Figure 3.2.10 Comparison of the interactions of residue 30 with UIC-94017 in
PRD30N and PR structures.
Interatomic distances are indicated by dashed lines with the separation in Å. The major
orientation of protease/inhibitor is colored by atom type and the minor orientation is shown in
magenta. Maps were contoured at 1.6σ. Hydrogen bonds between the aniline ring of UIC94017 and the main-chain atoms of residues 30/30’, which were essentially same for PR and
PRD30N, are not shown.
A. Direct H-bond between carboxyl oxygen of Asp30 of PR with UIC-94017.
Similar interaction was observed in the minor orientation of inhibitor.
B. 2Fo-Fc electron density map for residue Asn30 of PRD30N.
A water-mediated H-bond was observed between the side-chain of Asn30 to aniline ring.
C. 2Fo-Fc electron density map for residue Asn30’ of PRD30N.
The major orientation of protease/inhibitor is colored by atom type and the minor orientation
is shown in magenta sticks. Two alternate conformations of Asn30’ (56/44% occupancy
distributions) and water-mediated contacts to the aniline moiety of UIC-94017 were
suggested by clear maps. Interactions of bis-THF moiety are not shown.
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hydrogen bonds to the amide nitrogen atoms of residues 29 and 30 (and 29’, 30’ for the
other subunit) with the distances of 2.9-3.3 Å, which were similar to those of other four
UIC-94017 complexes (Table 3.2.4). No significant difference in hydrophobic
interactions was observed for PRD30N and PR complexes. The changes in hydrogen bond
network for PRD30N/UIC-94017 may contribute to its 30 times worse Ki compared to PR.
In PRI50V complex, a small bending of the major conformation of UIC-94017 was
observed. This bending of the aniline ring induced a very strong hydrogen bond (2.5 Å)
between p-NH2 and the carboxylate of Asp30 and in turn, prevented the formation of
other hydrogen bonds with the main-chain amide (3.4 Å) and carbonyl oxygen (4.1 Å) of
the same residue (Figure 3.2.11); while for the other subunit, the interactions with the
main-chain of Asp30’ were similar to those of the other four complexes (Table 3.2.4). In
addition to the changes in hydrogen bonding system, differences in hydrophobic
interactions were observed at the mutation site caused by the loss of one methyl group.
The sulfonamide oxygen atoms made close contacts with the terminal CH3 group of Ile50
(3.4 Å). In the I50V mutant structure, there was a small movement of 0.2 Å on the Cα of
Val50; yet, the valine isopropyl group was located opposite to the inhibitor and these
interactions with the SO2 moiety were even weaker (3.6-3.8 Å). Furthermore, the close
contacts between Ile50 and aniline aromatic ring (3.6-4.0 Å) were totally interrupted by
shorter side-chain of Val50 (>4.5 Å) (Figure 3.2.12A). On the other hand, Val50’ in
another subunit was oriented differently, so that the isopropyl group faced to the
inhibitor. A larger shift of 0.4 Å on Cα of Val50’ placed its two side-chain methyl groups
at positions capable of forming two strong and almost symmetric interactions (2.6 and 2.8
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Figure 3.2.11 Interactions of the aniline group of UIC-94017 with residue Asp30 in
PR and PRI50V structures.
PR is colored by the atom type while PRI50V in green sticks. The alternate conformation
of the Asp30 side-chain in PR, and the second orientation of the inhibitor for both
structures are omitted for clarity. The interactions of the other orientation of inhibitor
with residue Asp30’ of the other protease subunit are similar in all the structures.

A.

B.

Figure 3.2.12 Interactions of mutated residue with UIC-94017 shown in
superimposed PRI50V and PR structures.
Interatomic distances are indicated by dashed lines with the separation in Å. PR is shown
in magenta bonds (light magenta for the minor orientation of Ile50) and PRI50V is colored
by atom type. The interactions between CB atom of residue 50 and UIC-94017, which
are very similar for PR or PRI50V, and the second orientation of the inhibitor are omitted for
clarity.
A) PR compared to PRI50V near residue 50.
B) PR compared to PRI50V near residue 50’.
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Å) with each of the sulfonamide oxygen atoms (Figure 3.2.12B). The interactions from
Ile50’ CH3 group to aniline group were also partially maintained by Val50’ (~ 3.6 Å).
Therefore, similar to PRV82A, the small movement of main-chain atoms of residue 50’ in
PRI50V towards inhibitor UIC-94017 partly compensated for the change from isoleucine
in PR to a smaller amino acid valine in PRI50V. Moreover, the observed 9 times lower
inhibition constant for PRI50V compared to PR was supported by the structural evidence
of weaker hydrophobic contacts at mutation site 50/50’ and the loss of hydrogen bonds
with Asp30 in PRI50V/UIC-94017 complex.

Geometry of catalytic aspartates and implications for reaction mechanism
The four carboxylate oxygen atoms of Asp 25 and 25’ were arranged in almost
the same plane and were at distances of 2.4-3.3 Å from the hydroxyl oxygen of UIC
94017 in all the structures (Table 3.2.4). Two inner carboxylate oxygens of the two
catalytic aspartates lie within hydrogen bonding distance of each other in the HIV-1
protease structures (2.6-2.9 Å). Consequently, it has been assumed that one aspartate is
protonated and the other has a negative charge. The catalytic aspartates have been shown
to have different pKa values of 3.1 and 5.2, consistent with protonation of one catalytic
residue (Hyland et al. 1991). NMR measurements have also indicated that one of the two
catalytic aspartates was protonated in an HIV-1 protease-inhibitor complex (Wang et al.
1996). However, due to the symmetrical arrangement of the catalytic aspartates 25 and
25’ in the dimer of HIV protease it has been difficult to determine the location of the
expected proton. The existence and location of the proton has implications for the
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reaction mechanism. Solvent isotope effects were consistent with the reaction proceeding
by the rate-limiting step of dissociation of the enzyme-bound amide-hydrate intermediate
(Hyland et al. 1991). Recent kinetic studies using a fluorogenic substrate at pH 6.0 and
1.25 M salt to obtain the solvent isotope effects have also suggested that cleavage of the
carbon-nitrogen bond was the major contributor to kcat (Porter et al. 2002). The proposed
mechanism involves the catalytic aspartates together with a water molecule that acts as a
nucleophile in attacking the carbonyl carbon of the scissile bond. This mechanism is
difficult to support from the crystal structures of HIV protease with transition state
analogs, since there is little space for a water molecule next to the catalytic aspartates.
The closest water molecule cannot interact directly with the catalytic aspartates since it
lies at the opposite side of the scissile peptide bond next to Ile 50 and 50’ of the flaps.
The electron density for the catalytic aspartates can be examined for details
relevant to the reaction mechanism. The crystal structures of PR, PRI84V, PRD30N and
PRI50V showed little or no Fo-Fc difference density around the Asp 25 and 25’ side
chains, in particular, there is no positive difference density suggesting a proton. These
structures were refined at 1.2 to 1.5 Å resolution, and the lower resolution and disordered
inhibitor may mask any density for a proton. However, the atomic 1.10 Å resolution of
the PRV82A structure and the presence of ordered density for inhibitor revealed differences
in the electron density around the catalytic aspartates. In fact, significant Fo–Fc
difference density was observed for the carboxylate oxygens, in contrast to the other Asp
side chains in the structure (Figure 3.2.13). The two outer carboxylate oxygens (OD2)
showed negative difference density. A streak of positive density was observed between
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Figure 3.2.13 Electron density maps for catalytic aspartates of PRV82A.
The 2Fo-Fc map is green and was contoured at a level of 1.7 σ, whereas the Fo-Fc map is
contoured at 3.2 σ and colored red for positive and blue for negative. Polar interactions
are indicated by dashed lines with the interatomic distances in Å. The carboxylate
oxygen atoms of Asp 25 and 25’ are labeled.
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the hydroxyl group of the inhibitor and the inner and closest OD1 of Asp 25’ (2.5 Å
separation of OH and OD1), which may indicate a hydrogen atom. This positive density
is reduced, but not eliminated, when hydrogen is added to the Asp 25’ OD1. The unusual
negative difference density can be interpreted as a redistribution of the electrons in the
two C-O bonds in the Asp side chain to a less symmetric arrangement in which the C-O
bond furthest from the center has more double bond character, and the other has less.
Free atom refinement of the carboxylate groups gave distances of 1.27 Å for both C-O
bonds in Asp 25, while Asp 25’ showed asymmetry with 1.2 Å for C-OD1 and 1.3 Å for
C-OD2, consistent with protonation of OD1 (Figure 3.2.13). However, the free atom
refinement did not significantly change the negative density. Further analysis of the data
by charge density analysis or quantum calculations will be necessary to understand the
distribution of electrons at the active site. However, the difference densities suggest a
more complex mechanism than protonation of a carboxylate oxygen.

Discussion
The UIC-94017 inhibitor is in clinical trials for further development as a new
antiviral agent for treatment of primary and multi-PR inhibitor resistant HIV infections
due to its favorable pharmacokinetics (Koh et al. 2003). The hydrogen bond interactions
of UIC-94017 with HIV PR can be compared to those of substrate analogs. PR
recognizes peptide substrates and peptidic inhibitors by means of a series of hydrogen
bond interactions with the main chain atoms of the substrate, as observed for crystal
structures of PR in complex with substrate analogs (Gustchina et al. 1994). These
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interactions span about seven peptide residues lying in PR subsites S3-S4’ (Louis et al.
2000). The clinical inhibitors lie primarily in subsites S2-S2’ and generally show fewer
hydrogen bond interactions. The UIC-94017 inhibitor is shorter than the substrate analogs
and forms similar hydrogen bonds to PR main chain groups, including the conserved Asp
29 (Weber et al. 1997). In addition, new polar interactions are formed with the main
chain amide, carbonyl oxygen and the carboxylate oxygen of Asp 29. These interactions
resemble those of the P2’ Gln or Glu side chain of peptide analogs (Weber et al. 1997;
Mahalingam et al. 2001; Tie et al. 2005). These polar interactions of the bis-THF of
UIC-94017 were not observed for the most closely related clinical inhibitor, amprenavir.
Moreover, the PR/IDV structure contained only two direct hydrogen bonds to the PR
main chain, while six such interactions were present in the wild type and mutant
structures with UIC-94017. Hence, the UIC-94017 inhibitor more closely mimics many
of the natural substrates in the interactions with the PR main chain atoms than observed
for the other clinical inhibitors. Therefore, UIC-94017 may better adapt to mutations than
other clinical inhibitors, making it more difficult for the virus to select resistant
mutations.
The tight binding of the bis-THF group to the main chain atoms of Asp 29 and 30
are expected to be important for the potency of UIC-94017 against multi-drug resistant
HIV (Koh et al. 2003). Such interactions are probably less susceptible to resistant
mutations than those with the side-chain atoms. However, inhibition data for PRV82A,
PRI84V, PRD30N, PRI50V and PRL90M have shown that UIC-94017 does lose some affinity
for the mutated protease, especially in the case of I50V and D30N mutations. The
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relative Ki values were 3.6, 5, 9 and 30 for mutants PRV82A, PRI84V, PRI50V and PRD30N,
respectively (Table 3.2.1). In the case of PRI84V, an enlarged binding site cavity had been
observed and it showed fewer van der Waals interactions of residue 84 with UIC-94017,
consistent with a four-fold reduction in inhibition as compared to PR. Similar effect has
been reported for mutant I54V that also introduces a smaller amino acid (Clemente et al.
2004; Tie et al. 2004). In contrast, compensating conformational changes have been
observed in the crystallographic analysis of PRV82A and PRI50V. PRV82A showed
rearrangements of the main chain atoms around residue 82 and 82’, which permitted
closer interaction of Ala 82 and 82’ with UIC-94017, and partly compensated for the
fewer side chain atoms in Ala compared to Val. The structural rearrangements were
consistent with similar inhibition observed for both PRV82A and PR. The crystal structure
reported for PRV82A with the inhibitor A-77003, also showed rearrangements of the
backbone atoms in one subunit (Baldwin et al. 1995), while a recent study described
fewer interactions of Ala 82 with inhibitors saquinavir and ritonavir compared to those of
Val 82 (Prabu-Jeyabalan et al. 2003). On the other hand, there were more differences in
the interactions between the inhibitor and the protease in the PRI50V structure, in
agreement with its bigger change in Ki. Although the inhibitor’s aniline group (major
orientation) bent considerably from the position observed in any other structures (Figure
3.2.11) and decreased its contacts with the main-chain of Asp30, the hydrogen bond to
the side-chain carboxyl oxygen was shortened by 0.2 Å and became stronger. Therefore,
the strength of the aniline-to-Asp30 interaction might not be significantly affected.
However, PRI50V lost favorable interactions between the side chain of Val50 to the π-
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system of the inhibitor aniline moiety as observed for Ile50 in PR complex (Figure
3.2.12A), while the structural adjustment of Val50’ main chain and different
conformation of Val50 side chain partially maintained such hydrophobic contacts (Figure
3.2.12B). As expected, the mutation on residue 30, which can form tight hydrogen bonds
with UIC-94017, induced some effects on protease-to-inhibitor interactions. The inhibitor
had water-mediated contacts to the side chain of Asn30/30’; while in PR a direct
hydrogen bond was observed with one of the alternate conformations of Asp30/30’.
Since other interactions in the two structures (PR and PRD30N) were very similar, the
substitution of direct contacts by water-mediated interactions may help explain the 30
times higher Ki value for PRD30N compared to the wild-type PR. Besides, as hydrogen
bonds are stronger than hydrophobic contacts, it may explain why the Ki value increased
more for PRD30N than for PRI50V.
Structural and kinetic studies have suggested that mutations V82A and I84V,
which are common in drug resistant clinical isolates, had minor effects on the inhibition
of UIC-94017. So, they are expected to show resistance only in combination with other
mutations. Moreover, the kinetic measurements had shown that PRD30N was only 10% as
active as the wild type protease on the fluorescent substrate, while PRI50V was 40% as
active. On the other hand, the potency of UIC-94017 was reduced by about 30 and 9fold, respectively, for PRD30N and PRI50V. It implies that the mutations PRI50V and
especially PRD30N may be selected by the virus for resistance to UIC-94017.
Consequently, UIC-94017 is not expected to be a good salvage therapy candidate for the
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patients who have failed nelfinavir regimen due to the presence of the viral strains that
already contain the D30N mutation in the protease.
These new crystal structures of HIV PR mutants with UIC-94017 will provide the
framework for the design of new inhibitors that are more effective against resistant HIV.
The highest resolution structure of PRV82A mutant provides an intriguing view of the
catalytic residues and further analysis will help understand the protonation states of the
catalytic aspartates and the reaction mechanism. The results have been published in (Tie
et al. 2004; Kovalevsky et al. 2006).
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3.3 Structural analysis of complexes with saquinavir
Aim 3: To determine & analysis crystal structures of PR and mutants PRV82A and
PRI84V with saquinavir (SQV).
Saquinavir, the first protease inhibitor proved by FDA, is a peptide-like substrate
analog. The kinetic data and atomic resolution structures of wild-type PR, drug resistant
mutants PRV82A and PRI84V in complex with saquinavir were studied. These structures
will give the molecular based information to help understand the drug resistance to
saquinavir and provide valuable reference to compare with other PI drugs. The
comparison will help understand the structural advantage and disadvantage of compounds
and further help the design of more efficient next generation inhibitors.

Saquinavir inhibition of PRV82A and PRI84V
PR and the drug-resistant mutant proteases, PRV82A and PRI84V, catalyze the
hydrolysis of the fluorescent substrate, a synthetic peptide (Matayoshi et al. 1990; Wang
et al. 1990) based on the HIV-1 MA-CA cleavage site in the Gag-Pol polyprotein, and
their catalytic activities are competitively inhibited by saquinavir. Their saturation
kinetics with the same fluorescence assays were published previously (Kovalevsky et al.
2006); PRV82A had similar kcat/Km value as PR while that of PRI84V was 65% of PR
(Kovalevsky et al. 2006). The measured inhibition constants for saquinavir were 3.9 ± 0.8
nM for PR, 4.3 ± 0.7 nM for PRV82A, and 4.3 ± 0.4 nM for PRI84V. Surprisingly, the
mutants PRV82A and PRI84V had essentially the same Ki value as PR. In contrast, most of
the other clinical inhibitors showed significantly poorer inhibition of the PR with V82A
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or I84V mutations relative to wild type PR (Gulnik et al. 1995; Klabe et al. 1998).
However, this result is consistent with the rare appearance of mutations V82A or I84V,
rather than L90M and G48V, as primary mutations in HIV clinical isolates exposed to
saquinavir.

Crystal structures
The crystal structures of PR and drug-resistant mutants PRV82A and PRI84V have
been determined in their complexes with the clinical drug saquinavir. Crystallographic
statistics are summarized in Table 3.3.1. The PR/SQV structure was determined in the
P212121 space group while the structures of the two mutants were determined in both
space groups P21212 and P212121 with two different unit cells. Each crystallographic
asymmetric unit contains one protease dimer. All structures were refined at resolutions
of 0.97-1.25 Å and R factors of 0.12-0.15 including disordered residues, solvent
molecules, anisotropic B-factors and hydrogen atoms. The electron density was excellent
for all the atoms and especially for the sub-atomic resolution structure of PRV82A/SQV
complex. Saquinavir was observed in two alternate conformations in all structures, except
for the PRI84V/SQV complex in the P212121 space group. The relative occupancies of the
two conformations are listed in Table 3.3.1. The electron density map clearly showed two
alternate orientations of saquinavir (Figure 3.3.1A). Alternate conformations were also
observed for residues 79’-82’ (Figure 3.3.1B), which had direct interactions with
saquinavir, in all structures in the P212121 space group. Similar to our other structures
(Tie et al. 2004; Kovalevsky et al. 2006), the majority of residues with two alternate
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Table 3.3.1 Crystallographic data statistics.
Protease
Inhibitor
Space group
Unit cell
dimensions
(Å)

PR

P212121
52.10
a
59.78
b
62.49
c
50-1.16
Resolution range (Å)
67949
Unique reflections
7.5
Rmerge (%)
(34.8)
Overall (final shell)
14.6
<I/sigma>
(3)
Overall (final shell)
10-1.16
Data range for refinement (Å)
0.13
Rwork (%)
0.18
Rfree (%)
No.
of
waters
(total 185.5
occupancies)
96.6
Completeness (%)
(72.6)
Overall (final shell)
RMS deviation from ideality
0.017
Bonds (Å)
0.041
Angle distance (Å)
Average B-factors (Å2)
12.3
Main chain
17.6
Side chain
11.3
Inhibitor
33.4
Solvent
Relative occupancy of inhibitor 0.5/0.5

PRV82A

PRV82A
Saquinavir
P21212
P212121
59.99
51.13
87.46
58.59
47.19
61.61
50-1.10 50-0.97
95683
109869
11
10
(36.0)
(25.1)
10.5
20.5
(2)
(4)
10-1.10 10-0.97
0.15
0.12
0.18
0.14
217
182.2

PRI84V

PRI84V

P21212
58.58
86.00
45.83
50-1.25
64831
4.7
(50.6)
11.3
(2)
10-1.25
0.15
0.19
166

P212121
51.05
58.88
61.50
50-1.20
59108
6.5
(36.4)
11.1
(2)
10-1.20
0.15
0.20
138.2

94.6
(64.5)

89.3
(53.8)

92.8
(61.7)

92.6
(64.3)

0.020
0.045

0.016
0.035

0.013
0.033

0.013
0.033

13.7
19.5
13.3
35.2
0.5/0.5

8.8
13.3
9.4
22.1
0.7/0.3

15.8
21.7
14.2
30.4
1

15.0
21.9
16.7
28.8
0.7/0.3
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A.

B.

C

Figure 3.3.1 2Fo-Fc electron density map examples in PRV82A/saquinavir complex
structure.
Major conformation is colored by atom type while minor one by magenta.
A. Omit map of saquinavir (contoured at 3σ level)
B. 2Fo-Fc electron density at residue 79-82 (contoured at 1.8σ level)
C. 2Fo-Fc electron density at catalytic site (contoured at 1.8σ level)
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conformations had long side chains and were located at the surface of the protein, while
others were hydrophobic amino acids forming the inhibitor binding site, including Val82
and Ile84. The average B-factors were low for protein and inhibitor atoms, and decreased
as the resolution of the data increased. The B-factors were in the ranges of 8.8-15.8,
13.3-21.9, 8.7-16.7 and 22.1-35.2 Å2 for protein main chain atoms, side chain atoms,
saquinavir, and solvent atoms, respectively.

Saquinavir, the catalytic triad, flap residues and 80’s loop show correlated alternate
conformations at sub-atomic resolution
The atom positions are defined very accurately with the sub-atomic resolution
data for the PRV82A/SQV complex in the P212121 space group. Residues 24-26 and 24’26’ in the active site were observed in two conformations with the occupancy distribution
of 0.55 to 0.45 (Figure 3.3.1C), which was the same as that of saquinavir. This suggests
that the conformation of the active site residues is correlated with the alternate
conformations of the inhibitor saquinavir. After refinement with the two conformations
the partial positive and negative Fo-Fc density around the catalytic triad disappeared. As
shown in Figure 3.3.1C, the hydroxyl group on the saquinavir formed 2.6, 3.1, 2.9 and
2.7 Å long hydrogen bonds to Asp25 OD1, OD2, Asp 25’ OD1 and OD2 respectively.
The other orientation of the inhibitor showed the same arrangement and distances. These
more accurately determined atom positions of the active site residues may have not been
correctly modeled before in other structures with two conformations of inhibitor. Thus,
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the sub-atomic resolution data has more accurately described the detailed geometry of the
PR active site.
The tips of the flap, residues 48-52 and 48’-52’, were also modeled with two
conformations with the same relative occupancy as those of saquinavir. The major
orientation of the flap residues was correlated with the major conformation of saquinavir,
while the minor one correlated with the minor conformation of saquinavir. The main
chain peptide group of Ile50/50’ had two conformations related by a 180 degree flip, and
also the backbone of flap region residues 48-52/48’-52’ was moved about 0.2 Å to
provide more space for big P1’ ring of saquinavir.
The third region with alternate conformations was the 80’s loop in both subunits
(residues 79-82 and 79’-82’), as shown in Figure 3.3.1B. In the PR/SQV and PRI84V/SQV
structures (in the P212121 space group), the alternative conformations were observed only
in one subunit for residues 79’-82’. Since this region plays an important role in binding
inhibitor, it will be further discussed later.

Protease interactions with saquinavir
Saquinavir is a peptide-like inhibitor containing the main chain amides and
carbonyl oxygen atoms of a peptide and a variety of groups corresponding approximately
to the side chains at positions P3-P2’ of a peptide substrate (Figure 3.3.2). The large
hydrophobic groups at positions P3, P1 and P1’ of saquinavir fit into the hydrophobic
pockets S3, S1 and S1’ of the PR. There is a smaller hydrophobic t-butyl group at P2’
and the polar asparagine side chain at P2 of saquinavir. The P1 and P1’ groups of
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saquinavir formed van der Waals interactions with PR residues Leu23’, Asp25/25’,
Gly27, Ala28, Gly49’, Ile50, Thr80, Pro81, Val82’ and Ile84/84’. The other groups of
saquinavir interacted with residues Gly27, Ala28/28’, Asp29, Asp30/30’, Gly48/48’,
Gly49/49’, Ile50, Pro81’ and Ile84’. The residues 79’ to 82’ in the PR/SQV structure
interact closely with the saquinavir and showed alternate positions with the occupancy
distribution of 0.7 and 0.3. This suggests that the flexibility of this region allows the PR
to adapt to various subgroups on the different inhibitors. Theoretically, the flexibility of
the structure will increase the entropy and in turn reduce the interaction energy between
protein and inhibitor.
The PR hydrogen bond interactions with saquinavir are shown in Figure 3.3.3.
There were seven direct hydrogen bonds formed between protease and saquinavir. Four
hydrogen bonds were formed between the hydroxyl group of saquinavir and the side
chain carboxylate oxygen atoms of the catalytic Asp 25/25’, and the other three were
from O1 of saquinavir to the main chain amide of Asp29, from N3 to the amide nitrogen
of Asp30, and from N3 to the main chain carbonyl oxygen of Gly48. Two water
molecules mediated three more H-bond interactions. The conserved water linked the PR
flaps and saquinavir, and the other water mediated the interactions between O1 of
saquinavir and the main chain oxygen of Gly27 and side chain oxygen of Asp29. An
equivalent hydrogen bond network was observed for both conformations of saquinavir.
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Figure 3.3.2 van der Waals interactions between PR and saquinavir at different
subsites.

Figure 3.3.3 Hydrogen bond network between PR and inhibitor saquinavir.
Interactions mediated by water are shown in red.
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Comparison of the structures of PR and mutants
The three structures in the same space group of P212121 were very similar overall,
with calculated RMS deviations of 0.43 and 0.41 Å for C alpha atoms in PRV82A and
PRI84V, respectively, compared with PR. Saquinavir was bound in two conformations in
all complexes, except for PRI84V/SQV in the P212121 space group (Table 3.3.1).
Saquinavir has very similar conformation and interactions in the five crystal structures.
The wild type PR and mutants PRI84V and PRV82A had almost identical hydrogen bond
interactions with saquinavir, except that the hydroxyl of saquinavir was located more
asymmetrically with respect to the side chains of catalytic Asp25 and 25’ in the mutant
complexes (Figure 3.3.1C). The distances from O4 to OD1, OD2 of Asp25 and Asp25’
are 2.6, 3.1, 2.9 and 2.6Å in the mutants compared to 2.8, 2.9, 2.9 and 2.9 Å in the
PR/SQV structure. Consequently, the N4 and O3 atoms of P2 were about 0.2 Å closer to
residues 27 to 30 in the mutant structures. Both PRI84V and PRV82A showed shifts in the
position of the main-chain atoms at the site of mutation compared to those observed for
PR (Figure 3.3.4). The shifts of the alpha-carbon of Val84 were 0.25 Å and 0.3 Å in the
two subunits (Figure 3.3.4A). However, this movement was perpendicular to the plane of
the P1’ decahydroisoquinoline ring and did not alter the overall interactions. In fact, the
Ile84 side chain was located opposite to the inhibitor, and the close contacts of 84 CD1
with the C31, C32 and C33 atoms of saquinavir (3.5, 3.3, 3.7 Å, respectively) were
eliminated in the PRI84V mutant and substituted by the 3.8-4.0 Å contacts with residues 81
and 82 (Figure 3.3.4A). The PR and PRI84V had almost identical numbers of van der
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A.

B.
Figure 3.3.4 Shifts at residues 82-84 in mutant complex compared to PR/SQV.
Structure of PR/SQV is colored in magenta while PRV82A/SQV in blue and PRI84V/SQV
in green.
A. PRI84V/SQV compared to PR/SQV.
B. PRV82A/SQV compared to PR/SQV.
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Waals contacts with saquinavir, except for the P2 position where the main chain O2 atom
of saquinavir was 0.1-0.2 Å closer to Ile50’ of the flap in PRI84V.
A shift of 0.5 Å towards saquinavir was observed for the alpha-carbon of Ala82 in
both subunits of PRV82A (Figure 3.3.4B). Similar to PRI84V, the Val82 side chain was
located opposite to the P1’ ring and was separated further from saquinavir (4.3-4.9 Å
interatomic distances) in the PR structure than was the side chain of Ala82 in the mutant.
In the mutant with Ala82, the CB atom was 0.2 Å closer to the P1’ but the distances were
still greater than 4 Å. Yet, the Pro81 also shifted and formed van der Waals contacts of
3.7-4.0 Å with the C29, C30 and C31 atoms of the decahydroisoquinoline group of
saquinavir (Figure 3.3.4B), which were 0.3 Å closer compared to those of PR. The
movement of Ala82 in the other subunit allowed 0.1-0.2 Å closer interactions with the P1
benzene ring. Similar movements of Ala82 in PRV82A compared to PR have been
reported previously for complexes with substrate analogs or UIC-94017 (Tie et al. 2004;
Tie et al. 2005). In those structures the shifts partially compensated for the loss of van der
Waals interactions between Ala82 and inhibitor caused by the absence of the two methyl
groups of Val. No such compensating interactions were observed for saquinavir. All these
observations suggest that the mutation to smaller amino acids at residues 82 and 84 can
provide more space and freedom for the PR to accommodate the larger groups of
saquinavir. The observed minor structural adaptation of the mutants to accommodate
saquinavir was consistent with the very similar inhibition constants observed for mutants
and PR.
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Saquinavir complexes with PRV82A or the PRD25N/V82A (1MTB) inactive mutant
had similar structural differences as observed for comparison of the complexes with
peptide analogs (Tie et al. 2005). The hydroxyl oxygen of saquinavir was 0.23 Å closer
to the catalytic Asp25/25’, which suggested that the active PR with Asp25 was closer to
the transition state.

Comparison of PR/SQV with PR/UIC-94017
The PR complexes with saquinavir and UIC-94017 were compared to understand
how PR binds the two different inhibitors. Both UIC-94017 and saquinavir have a central
hydroxyl group which forms strong hydrogen bonds with all four carboxylate oxygens of
catalytic Asp25 and Asp25’. Both inhibitors share a water mediated interaction with the
flaps. UIC-94017 (Tie et al. 2004; Kovalevsky et al. 2006) formed seven other direct
hydrogen bonds with PR, including six with the main chain and side chain atoms of
Asp29 and Asp30/30’ (Figure 3.2.6A). In contrast, saquinavir showed three direct and
one water-mediated hydrogen bonds concentrated at one end of the inhibitor (P2 and P3)
including only two interactions with Asp29/30 (Figure 3.3.3). The hydrogen bond to
carbonyl oxygen of Gly48, which was observed in PR/SQV but not presented in PR/UIC94017, was similar to the interactions observed for substrate analogs at the P2 position
(Tie et al. 2005). The hydrophobic interactions dominated in PR/SQV. Saquinavir has
larger hydrophobic groups at P1 and P1’ that provide more van der Waals interactions
with PR than observed for UIC-94017 (99 contacts of less than 4.0 Å for PR/SQV
compared to 91 for PR/UIC-94017). The first generation PR inhibitor, saquinavir was
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designed to mimic the hydrophobic interactions between substrate and PR, while the
design goal for UIC-94017 was to reduce its susceptibility to mutations by making more
hydrogen bonds to the main-chain atoms of PR.
In order to accommodate the large decahydroisoquinoline ring at P1’ of
saquinavir the 80’s loop of residues 79-82 has undergone a conformational change by
comparison to its position in the PR/UIC-94017 structure (Figure 3.3.5). The 80’s loop
has moved away from the decahydroisoquinoline ring with a 1.7 Å movement of the
nitrogen atom of Pro81. This structural adjustment has allowed Pro81 to form favorable
van der Waals interactions of 3.8-4.2 Å separation with the tip of the P1’ ring. The other
subunit was different; the residues 79’-82’ have adopted two conformations. The major
conformation has shifted by 0.8 Å compared to the corresponding region of PR/UIC94017 and established 3.8-4.0 Å favorable contacts with the atoms at the tip of the P1
phenylalanine group of saquinavir. In the conformation with 49% population, the
nitrogen atom of Pro81’ was 1.8 Å away from its position in the PR/UIC-94017 complex,
which was comparable to the position described for the other subunit, and interacted with
the big P1’ ring of the minor conformation of saquinavir with interatomic distances of
3.6-4.0 Å. Two alternate conformations of residues 79’-82’ were observed in PR and
both mutant structures, while the other subunit showed two conformations only in the
PRV82A/SQV complex (Figure 3.3.1B). This result suggests that the 80s loop is
intrinsically flexible and its position may be influenced more by the properties of the
inhibitor than by the PR mutations in this loop.
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Figure 3.3.5 Comparison of P1’ and S1’ positions in PR/saquinavir and PR/UIC94017 complex structures.
Structure of PR/UIC-94017 is colored in red while that of PR/saquinavir in green.
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Comparison of the structures in two different space groups
Since the two mutant complexes were crystallized in both the P21212 and P212121
space groups, it was possible to analyze the structural differences due to different packing
in the two crystal lattices. The structures of PRV82A/SQV and PRI84V/SQV in the two
space groups showed RMS deviations on alpha carbons of 0.7 and 0.5 Å, respectively.
There were no major differences in the protease interaction with saquinavir in the two
space groups and the active site residues showed a very low RMS deviation of 0.1 Å.
The biggest difference was for the surface residues 37-42, where the RMS deviation was
over 1 Å. This region has lattice contacts with a symmetry related molecule in the P21212
space group but not in the other space group. The flexibility of this loop did not affect the
overall packing of the protease. The other major difference was that the 80’s loop in the
P21212 structure had a single conformation, whereas this region of the structure in
P212121 had two alternate conformations. This comparison confirmed that the differences
induced by lattice packing are mainly on the protein surface and have little effect on the
details of protease-inhibitor interactions.
Torsion angles were calculated for each residue in the PRV82A/SQV complex and
compared for the structures in the space groups P21212 and P212121 with different unit
cells to study the flexibility and packing of each PR residue. The dihedral angles of the
backbone (shown in Figure 3.3.6) and specific main-chain hydrogen bond interactions are
typically the key to protein folding. The observed range of the torsion angles and the
rotational degrees of freedom studied here provide valuable information to apply in
molecular models and predictions of protein structures. The average change in main
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Figure 3.3.6 Definition of the dihedral angles of protein backbone.

Table 3.3.2 Comparison of two space group P212121 and P21212 for PRV82A/SQV
complex.
Angle analyzed
Degree (exclude 37-41/37-41’)
Degree (include 37-41/37-41’)

psi
3.67
4.27

Average changes for all residues
phi
omega
chi1
4.20
2.40
8.22
4.53
2.49
9.34
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chain phi, psi and omega torsion angles, and side chain chi1 torsion angle for all residues
in the PRV82A/SQV complex in the two space groups is given in Table 3.3.2. The average
changes were 3-4.5, 2.5 and 8-10 degree for phi/psi, omega and chi1, respectively. The
dihedral phi and psi angles of the main chain are more restricted than the chi angles of the
side chain, yet there were some variations. The difference in phi angle for residues Leu38
and Gly40’ in the structures in the different space groups was over 50 degree, while other
residues had differences of less than 20 degree. As mentioned above, loop 37-42 is
located at the “shoulder” position leading to the flap of the PR and showed the biggest
RMS deviation between structures in the two space groups. About 9% of the residues had
differences (in phi angle) of 10 to 20 degree and most of these were located at the protein
surface. Another 18% residues differed by 5 to 10 degree and were located at various
positions: the dimer interface at both termini, the flaps and the residues in contact with
the saquinavir, such as residues 28-31 and 80-82. The plots of differences in phi angles
and in psi angles for each residue had similar shapes and distributions, which suggested
that the changes in the two angles were coupled. Again, residue Ser37 had the biggest
difference in psi angle of 68 degree, while Leu38’ and Pro39’differed by about 25 degree,
and all other residues varied by less than 20 degree. The big variation in phi and psi
angles of loop 37-42 was correlated with its different lattice contacts in the two space
groups. In P212121, this loop interacts with residues within the same dimer, while in
P21212 it forms hydrogen bonds with a symmetry-related dimer. Around 10% residues
had difference (in psi angle) of 10 to 20 degree and 20% residues had differences of 5 to
10 degree. There was less deviation in omega angles, where the change for all residues

125

was below 30 degree. 98% of protease residues showed difference of less than 10 degree
in the omega angle; the exceptions were Met36/36’, Ile64 and Gly49’.
The chi1 torsion angle of the side chain was much more flexible than the main
chain dihedral angles. About 10% of the residues had differences of over 20 degree. A
plot of the average change in torsion angles against amino acid type (excluding the loops
37-41/37’-41’ which were involved in different lattice packing interactions) (Figure
3.3.7) further proved that the chi1 angle had the largest deviation, especially for residues
with long side chains, such as Glu and Lys, and some hydrophobic residues, such as Pro
and Ile. For residues at the protein surface with different chi1 angles, for example: loop
residues 37-42, flap residue Lys55 and turn 64-65, the side chains can be perpendicular to
each other or even flipped by 180 degree, depending on the environment (see examples in
Figure 3.3.8). The difference in chi1 angle between structures in the two space groups
was in the range of 0-15 degree for the core residues of the protein. The most important
feature is that the changes in the chi1 angle showed no correlation with the changes in the
psi and phi angles. The chi1 angle appears to depend more on the property of the amino
acid and its chemical environment. Met was the only amino acid that had very similar and
relatively high change in all four studied torsion angles. However, this result may not be
significant since there are only four methionines in HIV-1 PR.
Comparison of the torsion angles for the structures solved in two space groups
suggested that structural flexibility is an important feature of the PR and may be essential
to its function. This analysis defines the level of freedom in torsion angles that should be
applied during the molecular modeling process.
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Figure 3.3.7 Average deviation of the torsion angle of different amino acid type between two space group P21212 and
P212121 for PRV82A/SQV complexes.
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A.

B.
Figure 3.3.8 Different side chain orientation of same residue in two different space
groups (P21212 and P212121) for PRV82A/SQV complexes.
Positions in P212121 is colored in black while those of P21212 in grey.
A. Residues around Lys55.
B. Residues around Glu21’.
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Discussion
These new atomic resolution structures have revealed details of the PR-saquinavir
interactions and the structural changes in the presence of mutations or between different
space groups. The PR interactions with saquinavir, the first FDA-approved anti-HIV
drug, can be compared to those with peptide analogs or more recent clinical inhibitors.
There were only seven direct and two water-mediated hydrogen bonds between
saquinavir and PR, and they were focused at the P3-P2 end of saquinavir. The van der
Waals interactions appeared to be the major contribution to the PR affinity for saquinavir.
The binding affinity is determined by the Gibbs energy equation, so it depends on the
enthalpy (∆H) and entropy (∆S) changes. Either making ∆H more negative or ∆S more
positive will improve the PR-inhibitor binding affinity. Saquinavir binding to HIV-1 PR
is enthalpically unfavorable and is driven by the large favorable entropy change
(Velazquez-Campoy et al. 2000). The big rigid hydrophobic groups of saquinavir tend to
maximize the gain in desolvation entropy with a small loss in conformational entropy due
to the burial of these hydrophobic groups. Recent antiviral PR inhibitors, such as UIC94017, were designed to enhance the strong and favorable hydrogen bonds with the main
chain atoms of the PR. UIC-94017 shows an enthalpically favorable binding to PR with
less dependence on the entropy. This design may also improve the specificity and provide
better water solubility. Ideally, the inhibitor design should combine the two approaches,
maintaining good hydrogen bonds with main chain atoms and improving the van der
Waals contacts in the PR subsites, in order to provide tight binding and more effective
inhibitors. In agreement with (Velazquez-Campoy et al. 2000), balancing the
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enthalpically favorable polar interactions and desolvation entropy induced by
hydrophobic groups will optimize the PR-inhibitor binding affinity and specificity.
Comparison of the complexes of saquinavir with the mutants has helped to
understand drug resistance. Shifts of 0.3 and 0.5 Å on the alpha carbon atom of the
mutated residue were observed for PRI84V and PRV82A, respectively, compared to the
position in wild type PR. These changes did not significantly alter the PR-saquinavir
interactions. The major difference at the active site was that the hydroxyl group on
saquinavir was located more asymmetrically between the side chains of catalytic Asp25
and 25’ in the mutant complexes. The observed minor structural changes in saquinavir
complexes were consistent with the closely similar inhibition constants of mutants and
PR. In contrast, other inhibitors have shown reduced inhibition and interactions with
mutant compared to wild type PR. In these saquinavir complexes, the mutation from
bigger to smaller amino acids allows more space to accommodate the bigger side chain at
P1’ of saquinavir.
The P1’ decahydroisoquinoline group of saquinavir is very big for the S1’ binding
site. Compared to PR/UIC-94017, residues 79-82 have moved away from the active site
while the residues 79’-82’ have adopted two conformations in order to accommodate the
big groups of saquinavir. The analysis further reveals that the 80s loop is intrinsically
flexible. The flexibility of 80s loop was observed in all three structures, PR, PRV82A and
PRI84V, which suggested that the structure of the 80s loop was more dependent on the
specific inhibitor than on the mutations. Moreover, shifts of the 80s loop were observed
for structures in both the P21212 and P212121 space groups, suggesting that these
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structural movements were evidence of the flexible nature of the PR rather than a
consequence of crystal lattice packing effects. Similar flexibility was described for the
9X mutant structure (Munshi et al. 2000). Other flexible areas in the protease have been
suggested, such as the residues 15-21, the flap region and both termini (Rose et al. 1998;
Swairjo et al. 1998; Ishima et al. 1999; Zoete et al. 2002). The flexibility of the PR
structure may play an important role in its function in viral replication (Piana et al. 2002a;
Piana et al. 2002b). Analysis of the non-active-site mutations, for example, mutations in
the flap or dimer interface, has shown that altering these flexible regions of HIV-1 PR
can influence the binding of inhibitors or substrates (Olsen et al. 1999; Liu et al. 2005).
The sub-atomic resolution structure of PRV82A/SQV has provided greater
structural detail and more accurate atomic positions to understand the subtle structural
changes induced by one single mutation. The results presented here will help better
understand the molecular mechanisms of drug resistance and will be useful in developing
more potent PR inhibitors.
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3.4 Object-oriented protein structure database integrated with analysis functions
About 240 HIV-1 protease structures are now available in PDB. In our lab, 50 or
more high-resolution crystal structures have been finished and more are still in progress.
It will be beneficial to design a powerful program to help organize these data as well as
automate the detailed structural analysis. Thus, an object-oriented HIV-1 protease
structure database was designed and tested. The 50 structures solved by our lab are the
primary data source for the database, although there is no limitation to cover other data.
The whole design is aimed to provide variant basic functions of structural analysis with a
powerful and flexible computing architecture.

Data format and syntax
HIV-1 protease structure data can be fully expressed by PDB format (PDB 2002).
Beside the general data available in PDB file, we extracted a few important items of
information to store in a relational table and designed a search engine based on the
combination:
a. Category: Each structure file will contain one protein component. It will be a
particular kind of protein, for example, HIV-1 protease.
b. Protein: For each kind of protein, it can be either wild type or different mutant.
c. Inhibitor: For this test set of HIV-1 protease structures, the inhibitor is a substrate
analog peptide with 7-11 amino acids or a synthesized small compound. Currently,
there are 16 different inhibitors.
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d. Space group: As some protein/inhibitor complexes can crystallize in different
space groups, this information is added to identify them.
e. PDB ID: Each protein structure deposited to the Protein Data bank is assigned a
unique four-digit ID code. The ID is unique so it can be used as a primary key to
search the database. However, the ID code itself does not provide any information
about the kind of protein or inhibitor involved and some structures which have not
gone through this stage will not have an ID.
f. Year: Similar to space group, different research groups may have solved the
structure for the same complex, or later on, a better resolution structure may be solved
and updated for the same complex. The year was added to help distinguish them.
Each PDB file is saved in database with above information in a row (called a
record). In order to make the design concise, each record for one structure was named by
the defined naming syntax. Each available property described above was presented by
one unique key and they are: C for category, P for protein, I for inhibitor, K for PDB ID,
S for space group and Y for the year of publication. The value for each key is enclosed by
a parenthesis and directly follows the key. A double mutant is indicated by two mutations
separated by underscore. For instance, a sample string of one record is given as
C(HIVPR)-P(D25N_V82A)-I(SQV)-K(1MTB). By the name, it tells that this is a HIV-1
protease double mutant D25N and V82A in complex with inhibitor saquinavir, which is
coded as 1MTB in PDB.
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Data searching, synchronization, storage and view
The search engine is used to narrow down the targets to be analyzed. Combined
search criteria are provided to filter out needed files. If no criterion is given, all files will
be selected. Once potential targets are defined, the system will automatically synchronize
the target data between backend database and the client. There will be a folder in client
program package which contains all the PDB files synchronized from the database. The
PDB files are named by the syntax described above according to the database
information. For the convenience of analysis, each PDB file will be parsed and
represented by a PDB object, and all the PDB objects will be saved into a vector for
future use. The PDB object reflects the construction of PDB file and was stored as a tree
structure, as shown in Figure 3.4.1. The PDB, chain, residue and atom are all defined
objects. The upper layer object has at least one lower layer object, and in most cases, it
contains a series of lower layer objects. In other word, upper layer object can be
considered as a container for lower layer objects. Therefore, they embody a parent-child
relationship. The Model-Control-View (MCV) strategy was adapted to display the HIV-1
protease structure data in this program. All the data are saved in a vector of PDB objects.
After all the target files been stored in local computer and parsed as objects, they
are arranged and displayed also as a tree on user’s interface. Generally, each structural
data runs across 6 levels or less in a tree and the last 4 level of nodes/leaves correspond to
objects PDB, chain, residue and atom. The root lists all available kinds of view mode
which can be used to display the tree and the arrangement of the second layer is
determined once a view mode is chosen. Three view modes are set up in the system; and
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Figure 3.4.1 Hierarchical object composition.
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they are View by Category, View by Proteins and View by Inhibitors. The mode of View
by Category will divide all target structure files into different kinds of protein. This
function is not fully developed and not applied now since only HIV-1 protease structures
are stored. The mode of View by Proteins will classify all structures according to HIV-1
protease/mutant type, while the mode of View by Inhibitors will display file names by
inhibitor type.

Analysis functions integrated within database
1. Data display and manipulation
Each PDB object will appear in the third layer of display tree with a link to text or
graphic display choice. User can select to open the whole PDB text file to gather the
detailed information needed, such as the structural factors, or open it with Rasmol (Sayle
et al. 1995) to view the 3D structure and use the command lines for further manipulation.

2. Distance calculation
a) Calculation among different levels of objects
As mentioned in the Methods, the interactions between protease and inhibitor are
generally characterized by the distances between atoms. Two atoms with separation of
about 4 Å are considered to form good van der Waals interactions, while those of 2.6 to
3.2 Å in distance and between a hydrogen bond donor atom and a hydrogen bond
acceptor atom are hydrogen bonds. The designed program employs the domain
knowledge and applies the polymorphism to the calculation. Regularly only two atom
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objects can be taken into the distance calculation. To make this function more efficient,
different layers of objects are allowed to be selected, such as a residue and a few atoms.
Once an object is selected, the program will automatically go to the lower level until the
leaf of atom object and take all the atoms within that object. Distances will be measured
between every pair of atoms out of all the atoms within two chosen objects. As shown in
Table 3.4.1, the system can support 9 kinds of combination of objects. The calculated
results will be filtered before being displayed on the screen. The filter is set up by two
numbers: minimum and maximum distances which are specified by the user. Afterwards,
the user can choose to store the results in excel format with user-defined file name for
future use.
b) Group calculation
As we are studying the subtle changes induced by different mutant or inhibitor,
sometimes it will be interesting to compare the interaction between the same two atoms
from different complexes, for example, to examine the geometry of two catalytic Asps
25/25’.
Since all the HIV-1 protease structure files from our lab have the same kind of
construction, it is possible to simplify this process. A group calculation is designed to
allow user to input two atom objects within one PDB first, and then put a collection of
selected PDBs that the user is interested in into the group. The system will retrieve the
types and structure positions of two input atoms and apply the calculation to the structural
equivalent atoms for all input PDBs. Again, the results can be saved as an excel file.
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Table 3.4.1 Calculation among different levels of objects.
1
2
3
4
5
6
7
8
9

Object1
Atom
Atom
Atom
Atom
Residue
Residue
Residue
Chain
Chain

Object2
Atom
Residue
Chain
PDB
Residue
Chain
PDB
Chain
PDB

Definition
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An example of distances between OD1 of Asp25 and OD1 of Asp25’ in selected
complexes is shown in Table 3.4.2.

3. Structure superimposing and visualization
Two structures can be compared by superimposing their main chain atoms using
program FUD. The system provides the superimpose function by calling FUD program.
A maximum of 8 HIV-1 protease structures can be selected to superimpose on one same
reference file at the same time. For each pair of calculation, one statistics file and one
superimposed PDB file will be generated and stored. For comparison convenience, these
results can be visualized in one graph generated by result files. In this graph, the RMS
deviations on Cα will be plotted against each residue. The global RMS deviation for each
pair of superimposed structures will be shown at the top corner of the graph (Figure
3.4.2). User can also choose to display individual statistics file in text.

Application and future approaches
This database has been applied to the analysis of UIC-94017 complexes and
saquinavir complexes discussed in 3.2 and 3.3. It provides an efficient tool to
superimpose and calculate interactions, as well as to present more complete and
quantified data to combine with the 3D structure visual program for analysis of detailed
structural differences. For future development, more analytical tools can easily be
incorporated into the database, such as a 3D structure visual program O or a more general
superimposition program. In that case, the superimposing will no longer be limited to the
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Table 3.4.2 Distances between OD1 of Asp25 and OD1 of Asp25’ in selected
complexes.
ATOM1
P(I84V)-I(SQV)-S(P21212).ent:
A:ASP:25:OD1:1.0
P(I84V)-I(SQV)-S(P212121).ent:
A:ASP:25:OD1:1.0
P(V82A)-I(SQV)-S(P21212).ent:
A:ASP:25:OD1:1.0
P(V82A)-I(SQV)-S(P212121).ent:
A:ASP:25:OD1:0.55
P(V82A)-I(SQV)-S(P212121).ent:
A:ASP:25:OD1:0.45
P(WT)-I(SQV)-S(P212121).ent:
A:ASP:25:OD1:1.0
P(I50V)-I(SQV).ent:
A:ASP:25:OD1:1.0
P(L90M)-I(IDV)-K(1SDU).pdb:
A:ASP:25:OD1:1.0
P(V82A)-I(IDV)-K(1SDV).pdb:
A:ASP:25:OD1:1.0
P(WT)-I(IDV)-K(1SDT).pdb:
A:ASP:25:OD1:1.0
P(G86A)-I(TMC114).pdb:
A:ASP:25:OD1:1.0
P(G86S)-I(TMC114).pdb:
A:ASP:25:OD1:1.0
P(D30N)-I(TMC114).pdb:
A:ASP:25:OD1:1.0
P(I50V)-I(TMC114).pdb:
A:ASP:25:OD1:1.0
P(I84V)-I(TMC114)-K(1S6S).pdb:
A:ASP:25:OD1:1.0
P(V82A)-I(TMC114)-K(1S65).pdb:
A:ASP:25:OD1:1.0
P(WT)-I(TMC114)-K(1S6G).pdb:
A:ASP:25:OD1:1.0

ATOM2
P(I84V)-I(SQV)-S(P21212).ent:
B:ASP:25:OD1:1.0
P(I84V)-I(SQV)-S(P212121).ent:
B:ASP:25:OD1:1.0
P(V82A)-I(SQV)-S(P21212).ent:
B:ASP:25:OD1:1.0
P(V82A)-I(SQV)-S(P212121).ent:
B:ASP:25:OD1:0.55
P(V82A)-I(SQV)-S(P212121).ent:
B:ASP:25:OD1:0.45
P(WT)-I(SQV)-S(P212121).ent:
B:ASP:25:OD1:1.0
P(I50V)-I(SQV).ent:
B:ASP:25:OD1:1.0
P(L90M)-I(IDV)-K(1SDU).pdb:
B:ASP:25:OD1:1.0
P(V82A)-I(IDV)-K(1SDV).pdb:
B:ASP:25:OD1:1.0
P(WT)-I(IDV)-K(1SDT).pdb:
B:ASP:25:OD1:1.0
P(G86A)-I(TMC114).pdb:
B:ASP:25:OD1:1.0
P(G86S)-I(TMC114).pdb:
B:ASP:25:OD1:1.0
P(D30N)-I(TMC114).pdb:
B:ASP:25:OD1:1.0
P(I50V)-I(TMC114).pdb:
B:ASP:25:OD1:1.0
P(I84V)-I(TMC114)-K(1S6S).pdb:
B:ASP:25:OD1:1.0
P(V82A)-I(TMC114)K(1S65).pdb:B:ASP:25:OD1:1.0
P(WT)-I(TMC114)-K(1S6G).pdb:
B:ASP:25:OD1:1.0

DISTANCE
2.66
2.85
2.82
2.78
2.86
2.91
2.87
2.79
2.67
2.64
2.49
2.58
2.64
2.79
2.59
2.87
2.85

Figure 3.4.2 An example superimposing result for saquinavir complexes.
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same kind/length of protein but based more on the structural similarity. A summary table
of certain information may be generated for selected PDBs. Furthermore, it can be
applied to proteins other than HIV-1 protease, for example, a large number of caspase
structures are being studied in our lab.
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4. General summary
HIV-1 PR is the most widely studied enzyme in the history of protein
crystallography. The valuable structural information was used to guide the development
of protease inhibitors; and indeed, these efforts have illustrated the enormous potential
and utility of the rational structure-based drug design strategy. However, drug resistance
is still a big obstacle in treating AIDS and its mechanism is not fully understood. To
better understand the molecular basis for the altered enzymatic properties and the
resistant phenotype and design more effective PIs to combat drug resistance,
crystallographic and kinetic studies were applied to three series of complexes:
I. wild-type HIV-1 protease (PR) and drug-resistant mutants, PRV82A, and PRI84V, in
complex with substrate analogs of five natural cleavage sites (CA-p2, p2-NC, p6polPR, p1-p6 and NC-p1);
II. PR, PRV82A, and PRI84V with current drug saquinavir;
III. PR, PRV82A, PRI84V, PRD30N and PRI50V, with latest antiviral inhibitor design UIC94017 (TMC-114).
The drug-resistant mutations V82A, I84V, D30N and I50V are all involved in forming
the substrate-binding site. A total of eighteen crystal structures have been refined at
resolutions of 0.97-1.60 Å. Observed structural changes were mostly consistent with the
relative inhibition data.
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Comparison of different inhibitors
For the first series, eight crystal structures of PR, PRV82A and PRI84V were
determined with reduced peptide analogs that represent the CA-p2, p2-NC, p6pol-PR, p1p6 and NC-p1 cleavage sites to provide details of the PR interaction with reaction
intermediates and better understanding of the substrate specificity. Substrate analogs
bound to PR through amino acid positions P4 to P4’ (P5 to P5’ for longer analogs p6polPR and p1-p6). Differences in the PR-analog interactions depended on the peptide
sequence and were consistent with the relative inhibition. Analog p6pol-PR formed more
hydrogen bonds of P2Asn with PR and fewer van der Waals contacts at P1’Pro compared
to those formed by CA-p2 or p2-NC in PR complexes. The P3Gly in p1-p6 provided
fewer van der Waals contacts and hydrogen bonds at P2/P3 and more water-mediated
interactions. The structures suggested that the binding affinity for mutants was modulated
by the conformational flexibility of P1 and P1’ side chains in the substrate analogs.
Unlike the longer substrate analogs which have more extended interactions within
PR subsites S4 to S4’, the clinical inhibitors maximize the contacts within S2 to S2’. The
UIC-94017 is a potential next generation drug in clinical trial while saquinavir, indinavir
and amprenavir have been used clinically for many years. All four inhibitors (UIC94017, saquinavir, indinavir and amprenavir) have the same central hydroxyl group
which formed strong hydrogen bonds with all four carboxylate oxygens of catalytic
Asp25 and Asp25’. Besides these four contacts, seven direct hydrogen bonds were
established between PR and UIC-94017, whilst three direct hydrogen bonds and three
water-mediated interactions (except the one water between the PR flaps and the inhibitor)
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for PR and indinavir. Three direct hydrogen bonds and one water-mediated interaction
were observed between PR and only one end of saquinavir, and nevertheless, only two
direct hydrogen bonds were observed for PR and amprenavir. The comparison showed
that although UIC-94017 was smaller than the substrate analogs, it more closely mimics
many of the natural substrates in the interactions with the PR main chain atoms than
observed for the other clinical inhibitors, especially the additional polar interactions with
the main chain atoms of Asp 29 and Asp 30. These interactions resembled those of the
P2’ Gln or Glu side chain of peptide analogs and have been proposed to be critical for the
potency of this compound against multiple PI resistant HIV isolates. On the other hand,
hydrophobic interactions were the major force for saquinavir binding. 10% more van der
Waals interactions were observed for PR/SQV complex than in PR/UIC-94017. In brief,
the design of early protease inhibitors, such as saquinavir, and the latest compound, UIC94017 has different approaches. The earlier inhibitors are more similar to nature
substrates. They mimic the hydrophobic side chains of substrate and tend to maximize the
gain in desolvation entropy with a small loss in conformational entropy due to the burial
of these big hydrophobic groups when they binds to protease. The latter approach of
producing an enthalpically favorable process with less dependence on the entropy by
introducing polar groups at inhibitor positions to form strong hydrogen bonds with the
main chain of protease may improve the specificity, be less susceptible by the mutations
and provide better water solubility. Ideally, the inhibitor design should combine both
approaches, balancing the enthalpically favorable polar interactions and desalvation
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entropy induced by hydrophobic groups, in order to provide tighter binding and more
effective inhibitors.
The comparison of structures with saquinavir to those of UIC-94017 also showed
an adjustment of the 80s loop (residues 79-82), which helped protease to accommodate
the large groups of saquinavir. Analysis suggested that this 80s loop was intrinsically
flexible and its conformation depended more on the nature of the inhibitor rather than the
mutations in this loop.

Comparison of different mutant
Structural and kinetic studies have suggested that mutation V82A, which is
common in drug resistant clinical isolates, had least effect on the inhibition of substrate
analogs, saquinavir and UIC-94017. The reason is that PRV82A was able to compensate
for the loss of interactions with inhibitor caused by mutation by the shifts of the backbone
of Ala82/82’. Furthermore, the complexes of PRV82A/substrate analogs showed smaller
shifts relative to PR, but more movement of the peptide analogs, compared to complexes
with clinical inhibitors. Another common drug-resistant mutation I84V had only the
minor effect on the inhibition of substrate analogs, saquinavir and UIC-94017. There
were less movement observed for PRI84V structures except for the saquinavir complex
(0.3 Å for the alpha carbon of Val84), so PRI84V simply lost favorable van der Waals
interactions with inhibitor compared to PR. The structural comparison of these two
mutant complexes suggested that substrate analogs have more flexibility than the drugs to
accommodate the structural changes caused by mutation, which may explain how HIV
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can develop drug resistance while retaining the ability of PR to hydrolyze natural
substrates. Moreover, in saquinavir structures, the mutation from bigger to smaller amino
acids allowed more space to accommodate the larger group at P1’ of saquinavir rather
than alter the protease-inhibitor interactions as seen in other inhibitors complexes.
In PRI50V, the UIC-94017 lost favorable hydrophobic interactions with the side
chain of Val50, while partial compensating conformational change had been observed on
Val50’ main chain. Similarly, in PRD30N the inhibitor had a water-mediated interaction
with the side chain of Asn30/30’ rather than the direct interaction observed in PR. In
addition, the kinetic measurements had shown that PRD30N was only 10% as active as the
wild type protease on the fluorescent substrate, while PRI50V was 40% as active; and the
potency of UIC-94017 was reduced by about 30 and 9-fold, respectively, for PRD30N and
PRI50V. Both structural and kinetic studies implied that the mutations PRI50V and
especially PRD30N might be selected by the virus for resistance to UIC-94017.
Consequently, UIC-94017 is not expected to be a good salvage therapy candidate for the
patients who have failed nelfinavir treatment due to the existence of the viral strains that
already contain the D30N mutation in the protease.
In summary, the development of drug-resistance to PR inhibitors is complicated
and can arise by more than one mechanism. No direct relationship was observed between
relative catalytic activity, inhibition, and structural stability of the different PR mutants.
Changes in any one of these parameters may cause drug resistance. Selected
compensatory mutations may be developed in virus after the initial mutation which
lowers the affinity for the inhibitor or the catalytic activity or dimer stability, to restore
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the optimal polyprotein processing and replication capacity in the presence of PR
inhibitor.

Advantage of atomic resolution data
With the high resolution crystal structures, the atom positions were more
accurately defined. Three shells of water molecules, solvent ions (such as sodium ion)
and molecules (such as glycerol and DMSO) were resolved. The 0.97 Å resolution data
for the PRV82A/SQV complex had shown more residues with alternative conformations
than seen before, especially the two conformations were observed for the active site
residues 24-26 and 24’-26’ and they were correlated with the alternate conformations of
saquinavir. The hydroxyl group on the saquinavir had similar arrangement and distances
to catalytic Asp25/25’ in both conformations. These precise positions of the active site
residues may have not been correctly modeled before in other structures with alternate
conformations of inhibitor. Thus, the sub-atomic resolution data has helped to describe
the detailed geometry of the enzyme active site.
Furthermore, the 1.10 Å crystal structure of PRV82A with one orientation of UIC94017 showed an unusual distribution of electron density for the catalytic aspartate
residues, which may be related to the reaction mechanism. A streak of positive density
was observed between the hydroxyl group of the inhibitor and the inner and closest OD1
of Asp 25’ (2.5 Å separation of OH and OD1), which might indicate a hydrogen atom.
However, the observation can hardly be proved only by the extra electron density.
Further analysis of the data by charge density analysis or quantum calculations will be
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necessary to understand the distribution of electrons at the active site. Yet, the difference
densities suggested a more complex mechanism than protonation of a carboxylate
oxygen.

Advantage of the database incorporated with analysis programs
For proteins that serve as drug-design targets, it is important to study proteaseinhibitor interactions accurately, completely and in as many complexes as possible.
Careful analysis of the wild-type as well as drug-resistant mutants of HIV PR may also
help in creating new drugs that would overcome the problem of resistance. The HIV-1
protease structure database offers an easy way to organize data and provides specialized
tools to automate the superimposing and distance calculation. The presence of such tools
and the ability for future development will help in better understanding the structural
phenomena related to HIV PR.

Other designed inhibitors under development
With the goal to design more effective protease inhibitors to combat drug
resistance, a series of similar compounds based on the structure of UIC-94017 had been
synthesized by Dr. Arun Ghosh’s lab and used for kinetic and crystallographic studies (as
listed in Appendix I) with HIV-1 PR. The data for UIC-98065 and UIC-00072 has been
completed. The detailed structural information would help evaluate the design goal and
provide valuable reference for further drug development.
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Overall, the large amount of kinetic and crystallographic studies has increased the
knowledge of enzyme function, structure, and catalytic mechanism and led to a better
understanding of how these drug-resistance mutations exert their effects at a molecular
level. These insights are valuable for the design of new drugs and therapeutic strategies to
combat drug resistance to AIDS.
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APPENDIX II. Structure prediction of BLV PR
Introduction
All replication competent retroviruses, including bovine leukemia virus (BLV),
code for an aspartic protease (PR). The function of the mature PR is critical for virion
replication (Oroszlan et al. 1990). As discussed above, the HIV-1 PR has proved to be the
most effective target of antiviral therapy; however, the application of PR inhibitors was
largely limited by rapidly development of drug resistance variants (Tamalet et al. 2000).
The residues observed in HIV-1 PR drug resistant frequently can be found in structurally
equivalent positions in other wild type proteases, as indicated for BLV PR in Figure 5.1.
Comparison of various retroviral proteases will reveal the common features of their
specificity; and furthermore, help the design of new antiviral inhibitors that are efficient
against several different retroviral proteases.
The amino acid sequences of different retroviral proteases have been determined
(Oroszlan et al. 1990). The 3-D structures of seven proteases from HIV-1, HIV-2, SIV,
RSV, FIV, EIAV and HTLV-1 are also available (Wlodawer et al. 2000; Li et al. 2005).
The alignment of the primary and secondary structures of all retroviral proteases
suggested a single domain of the cellular aspartic proteases. Comparison of the predicted
PR structures of HIV-1, FIV and EIAV proteases with their latest crystal structures
proved that the models were basically correct in prediction of the substrate binding sites
(Weber 1991; Wlodawer et al. 1995; Gustchina et al. 1996). Therefore, the molecular
modeling of proteases can serve as an important tool in the absence of crystal structures.
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Figure 5.1 Sequence comparison of BLV, HTLV-1 and HIV-1 proteases.
Residues in BLV PR which appear in HIV-1 drug resistance at the equivalent position in HIV-1 PR are underlined (analyzed based
on hivdb.stanford.edu).
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Method
The sequence alignment of the BLV PR, HIV-1 PR and RSV PR was shown in
Figure 5.1. The crystal structure of the HTLV-1 PR with a substrate-based statine
inhibitor (Li et al. 2005) was the basis for the model for BLV PR. The BLV dimer was
modeled with the peptide substrates TKVL-VVQP using the program AMMP (Harrison
1993), as described previously for HTLV PR (Tozser et al. 2000). A conserved water
molecule was included between the flaps and the peptide and a proton was used to
stabilize the charged oxygen atoms of the two catalytic Asp residues. The positions for all
new atoms were generated with the sp4 potential set using 15 cycles of the Kohonen
algorithm (Harrison et al. 1999), followed by minimization of the non-bonded and
geometrical terms using 320 steps of conjugate gradients. Finally, the entire PR-substrate
complex was minimized using 10 cycles of total ~ 4000 steps of conjugate gradients.
Structural models were examined using the molecular graphic programs Sybyl (Tripos Inc.)
run on Silicon Graphics workstations, ’O’ (Jones et al. 1991) or RasMol (Sayle et al. 1995)
run on Linux PCs.

Results
Modeled structure of the BLV protease and comparison with the structures of
HTLV-1 and HIV-1 proteases.
In the absence of a crystal structure for the BLV PR, a model was built with a
peptide substrate in order to understand the molecular basis for the specificity. The amino
acid sequence of BLV PR was aligned with the sequences of HIV-1 PR and HTLV-1 PR,
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the structures of which are known, to find the best starting structure for building the model,
as shown in Figure 5.1. The lengths of the BLV, HTLV-1 and HIV-1 proteases are
different. The HIV-1 PR is the shortest one with 99 residues, followed by the HTLV-1
PR (125 residues), while BLV PR has 126 residues. Since BLV PR and HTLV-1 PR have
comparable length and higher similarity, HTLV-1 PR was chosen as the initial model.
Regardless of the difference lengths, the modeled BLV PR structure shared a conserved
core region with the crystal structures of HIV-1 and HTLV-1 proteases, including the
substrate binding site and the dimer interface (Figure 5.2). As shown in Figure 5.2, BLV
and HTLV-1 proteases formed longer loop structures on the surface of the proteins.
Besides, the C-termini extended by 10 additional amino acid residues for BLV and
HTLV proteases compared to the HIV-1 PR. The function of the C-terminal extension is
still controversial. Based on previous studies, these residues are not required for activity
(Precigoux et al. 1993; Herger et al. 2004), while other group suggested that five
additional C-terminal residues (116-120) appeared to be important for HTLV-1 protease
(Hayakawa et al. 1992). The final model of the BLV PR dimer with substrate had a RMS
deviation of 0.79 Å for 223 pairs Cα atoms of compared to the crystal structure of HTLV-1
PR and 1.72 Å for 175 pairs of Cα atoms of compared to the crystal structure of HIV-1 PR
(PDP code 2AOD). These RMS deviation values are comparable to that of 1.25 Å
observed for 194 pairs of Cα atoms in the dimers of RSV S9 PR and HIV-1 PR with
inhibitor (Wu et al. 1998). Residues forming the substrate binding sites of BLV, HTLV-1
and HIV-1 proteases are listed in Table 5.1 and a schematic representation with a HTLV-1
capsid-nucleocapsid substrate is shown in Figure 5.3.

Figure 5.2 Ribbon models of the BLV, HTLV-1 and HIV-1 PR structures.
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Table 5.1 Residues predicted to form the subsites of BLV, HTLV and HIV proteases.
_____________________________________________________________________________
Subsite
BLV/HTLV-1/HIV-1 Residuesa
_____________________________________________________________________________
S4:

Glu37/Asp36/Asp29, Asn38/Met37/Asp30, Ala56/Ser55/Met46,
Val57/Val56/Ile47, Leu58/Leu57/Gly48, Tyr68/Phe67/Val56, Trp70/Leu69/Gln58,
Leu92/Leu91/Leu76

S3:

Arg9'/Arg10'/Arg8', Leu31'/Leu30'/Leu23', Glu37/Asp36/Asp29,
Leu58/Leu57/Gly48, -/-/Thr80’b, -/-/Pro81', Trp99'/Trp98'/Val82'

S2:

(Gly35/Gly34/Gly27), Ala36/Ala35/Ala28, (Glu37/Asp36/Asp29), Asn38/Met37/Asp30, Val40/Val39/Val32, Val57/Val56/Ile47,
Leu58/Leu57/Gly48,(Gly59/Gly58/Gly49), Ala60'/Ala59'/Ile50', Tyr68/Phe67/Val56, Leu92/Leu91/Leu76, Ile101/Ile100/Ile84

S1:

Arg9'/Arg10'/Arg8', Leu31'/Leu30'/Leu23', (Asp33/Asp32/Asp25), (Asp33'/Asp32'/Asp25')
(Gly35/Gly34/Gly27), (Gly59/Gly58/Gly49) Ala60/Ala59/Ile50, -/-/Thr80’b, -/-/Pro81', Trp99'/Trp98'/Val82', Ile101'/Ile100'/Ile84'
__________________________________________________________________________
a

Residues that are different in all three proteases are indicated in bold, while residues differing in two proteases are indicated in
italics. Amino acid residues in the second subunit are indicated by a prime. Only the residues forming the S4-S1 subsites are given.
Primed binding sites (like S1') have the same composition as the nonprimed ones, but they are built from residues of the other
subunit. Residues involved only in interactions with the main chain atoms of the peptide substrate are shown in parenthesis.
b
While Thr80’ and Pro81’ of HIV-1 PR participate in the formation of the binding sites, the corresponding residues of BLV and
HTLV-1 proteases do not interact with ligand; their position is very different, due to an upstream loop insertion.
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L58/L57/G48
N38/M37/D30
A56/S55/M46
V57/Val56/I47 A60’/A59’/I50’
-/-/T80’
L92/L91/L76

S4

S1’

-/-/T80
-/-/P81
W99/W98/V82

S2

L58’/L57’/G48’

P1’ Val

P2 Val

P4 Thr

P3’ Gln
P1 Leu

P2’ Val

P3 Lys

L58/L57/G48

S3
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W99’/W98’/V82’

S3’
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Figure 5.3 A schematic representation of the HTLV-1 capsid-nucleocapsid substrate
in the S4-S3’ subsites of BLV, HTLV-1 and HIV-1 proteases.
The relative size of each subsite is indicated approximately by the area enclosed by the
curved line around each substrate side chain. PR residues forming the subsites are shown
only for those that differ between at least two PRs as BLV/HTLV-1/HIV-1 residues.
Residues of BLV PR that were mutated in this study are underlined.
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The specificity of the BLV PR was studied with a set of oligopeptides
representing naturally occurring cleavage sites in various retroviruses by Dr. Tozser’s
group. They have concluded that the BLV PR had a broad specificity, which is different
from HTLV-1 PR but similar to HIV-1 PR, and a great sensitivity towards mutations as
previously observed for the HTLV-1 PR. Furthermore, the BLV PR was more susceptible
towards inhibitors designed against either HIV-1 PR or HTLV-1 PR compared to the
susceptibility of the HTLV-1 PR (Sperka et al. 2006).

